Steve Sisolak Governor

Margaret Colucci, DC
President
Nicole Canada, DC
Vice President
James T. Overland Sr., DC
Secretary-Treasurer



Morgan Rovetti, DC

Member

Xavier Martinez, DC

Member

Tracy DiFillippo, Esq.

Consumer Member

John Bertoldo, Esq.

Consumer Member

Julie Strandberg
Executive Director

CHIROPRACTIC PHYSICIAN'S BOARD OF NEVADA

4600 Kietzke Lane, M-245 | Reno, Nevada 89502-5000

Phone: (775) 688-1921 | Fax: (775) 688-1920

Website: http://chirobd.nv.gov | Email: chirobd@chirobd.nv.gov

NOTICE OF MEETING

DATE: Thursday, January 14, 2021 **TIME:** 8:30 a.m.

LOCATION: Video Conference Call via Zoom

Instructions for attending conference call:

Link to Join / meeting Online:

Julie Strandberg is inviting you to a scheduled Zoom meeting.

Topic: Chiropractic Physicians' Board of Nevada

Time: Jan 14, 2021 08:30 AM Pacific Time (US and Canada)

Join Zoom Meeting

https://zoom.us/j/93532951046?pwd=Sm9QUUNpSXFIYXJJR1kwVUZ6bnRRZz09

Meeting ID: 935 3295 1046

Passcode: 038558 One tap mobile

+13462487799,,93532951046#,,,,*038558# US (Houston)

+16699006833,,93532951046#,,,,*038558# US (San Jose)

Dial by your location

+1 346 248 7799 US (Houston)

+1 669 900 6833 US (San Jose)

+1 253 215 8782 US (Tacoma)

+1 312 626 6799 US (Chicago)

+1 929 205 6099 US (New York)

+1 301 715 8592 US (Washington D.C)

Meeting ID: 935 3295 1046

Passcode: 038558

Find your local number: https://zoom.us/u/aeEu5g1Z9k

NOTE: Per Emergency Order 006 issued by Governor Sisolak on March 22, 2020, there will be no physical location for this meeting.

PLEASE DO <u>NOT</u> ATTEND THIS MEETING AT THE BOARD'S OFFICE.

NOTE: ALL AGENDA ITEMS ARE FOR DISCUSSION AND FOR POSSIBLE ACTION UNLESS OTHERWISE NOTED. AGENDA ITEMS MAY BE TAKEN OUT OF ORDER, COMBINED FOR CONSIDERATION BY THE BOARD, OR PULLED OR REMOVED FROM THE AGENDA AT ANY TIME.

AGENDA

Call to order - determine quorum present.

Pledge of Allegiance – Dr. Colucci Statement of Purpose – Dr. Overland

Agenda Item 1 Public Interest Comments - No action.

- A. Public Comment will be taken at the beginning and at the end of each Board meeting;
- B. Public Comment may also be taken at other such times as requested so long as the request that Public Comment be taken will not interrupt ongoing Board business;
- C. Depending on the number of individuals wishing to address the Board, a reasonable time limit may be set. The Board will not restrict comments based upon viewpoint;
- D. No action may be taken upon a matter raised during Public Comment until the matter itself has been specifically included on an agenda as an item upon which action may be taken.
- E. Prior to the commencement and conclusion of a contested case or a quasi-judicial proceeding that may affect the due process rights of an individual the Board may refuse to consider public comment as per NRS 233B.126.

Agenda Item 2 Approval of agenda – For possible action.

The Board reserves the right to address items in a different order or combine two or more items to accomplish business in the most efficient manner. An item may be removed from the agenda or discussion may be delayed relating to an item at any time.

Agenda Item 3 Approval of the October 15, 2020 Board Meeting Minutes. - For possible action.

<u>Agenda Item 4</u> Ratification of granting of DC licenses to applicants who passed the examination from October to December 2020 – For possible action

Agenda Item 5 Legislative Matters – For possible action.

A. Strategies 360 – Dan Musgrove

<u>Agenda Item 6</u> Discussion and possible action regarding CBD-containing products – For possible action

<u>Agenda Item 7</u> Discussion and possible action regarding amending the contract with Strategies 360 to extend the term and other potential amendments – For possible action.

<u>Agenda Item 8</u> Discussion and potential action regarding the application for licensure of Carl Damailig, DC - For possible action. (Note: The Board may go into closed session pursuant to NRS 241 to consider the character alleged misconduct, or professional competence of Dr. Dimailig)

<u>Agenda Item 9</u> – Discussion and possible action regarding the handling of requests to consider proof of formal chiropractor's assistant training pursuant to NAC 634.344 (4) (b) – For possible action

<u>Agenda Item 10</u> Consideration of including the supervising chiropractic physicians' signature on the Chiropractor's Assistant application – For possible action.

<u>Agenda Item 11</u> Consideration of potential additions, deletions, and/or amendments to NRS 634 and NAC 634– For possible action.

A. Discipline for failing to submit Self-Inspection by March 31.

<u>Agenda Item 12</u> Consideration of a policy and procedure about how agenda items may be put on an agenda for the Board's consideration. – For possible action

<u>Agenda Item 13</u> Discussion and possible action regarding chiropractic physicians including Qualified Medical Examiner (QME) on their Nevada letterhead – For possible action

<u>Agenda Item 14</u> Discussion and potential action regarding chiropractic physicians whose licenses expired effective January 1 and potentially may be continuing to practice on expired licenses – For possible action

Agenda Item 15 Status report regarding anonymous profiles of possible disciplinary actions. Board action will be limited to either dismissing the matter if the Board determines there is no violation, it has no jurisdiction over the subject, or providing direction to pursue the matter further – For possible action:

- A. Complaint 17-28S (Colucci)
- B. Complaint 18-13S (Rovetti)
- C. Complaint 18-15S (Canada)
- D. Complaint 18-17S (Canada)
- E. Complaint 19-03S (Canada)
- F. Complaint 19-12S (Rovetti)
- G. Complaint 19-16S (Canada)
- H. Complaint 20-01N (Rovetti)
- I. Complaint 20-03N (Rovetti)
- J. Complaint 20-04N (Colucci)

- K. Complaint 20-10S (Martinez)
- L. Complaint 20-12S (Canada)
- M. Complaint 20-13S (Colucci)
- N. Complaint 20-14S (Colucci)
- O. Complaint 20-15N (Canada)

Agenda Item 16 Board Counsel Report – No action.

Agenda Item 17 FCLB/NBCE Matters – For possible action.

- A. Selection of Board's choice for FCLB Voting Delegate
- B. Selection of Board's choice for FCLB Alternate Delegate
- C. Selection of Board's choice for NBCE Voting Delegate
- D. Selection of Board's choice for NBCE Alternate Delegate
- E. Attendance of Board Member(s) at the FCLB annual conference to be held in West Palm Beach, FL April 28 May 2, 2021
- F. Selection of Board Member to participate in the Spring National Board Part IV Exam May 21-23, 2021
- G. Selection of Board Member to participate in the National Board Part IV Test Committee meeting June 11-12, 2021
- H. Selection of Board Member to participate in the Fall National Board Part IV Exam November 12-14, 2021

Agenda Item 18 Committee Reports

- A. Continuing Education Committee (Dr. Martinez) For possible action.
- B. Legislative Committee (Dr. Colucci) For possible action.
- C. Preceptorship Committee (Dr. Rovetti) For possible action.
- D. Test Committee (Dr. Canada) For possible action.

Agenda Item 19 Executive Director Reports:

- A. Status of Pending Complaints No action.
- B. Status of Current Disciplinary Actions No action.
- C. Legal/Investigatory Costs No action.
- D. Board Audit (Bertrand & Associates)
- E. Contract with Bertrand & Associates

Agenda Item 20 Financial Status Reports:

- A. Current cash position & projections No action.
- B. Accounts Receivable Summary No action.
- C. Accounts Payable Summary No action.
- D. Employee Accrued Compensation No action.
- E. Income/Expense Actual to Budget Comparison as of September 30, 2020 No action.
- F. Budget to Actual at September 30, 2020 No action.

Agenda Item 21 NCA Report – No action

Agenda Item 22 NCC Report – No action

Agenda Item 23 Public Interest Comments – No action.

This portion of the meeting is open to the public to speak on any topic NOT on today's agenda and may be limited to 3 minutes.

<u>Agenda Item 24</u> Adjournment – For possible action.

Per Emergency Order 006 issued by Governor Sisolak on March 22, 2020, Board Agendas are only posted at the following locations:

Office of the Chiropractic Physicians' Board of Nevada – Reno, Nevada
The Website for the Chiropractic Physicians' Board of Nevada – www.chirobd.nv.gov
Nevada Public Notices Website- www.notice.nv.gov

Board Meeting Agendas and Minutes are posted on our website: www.chirobd.nv.gov

Supporting meeting material may be obtained by contacting the Board by phone, fax or email. You may directly contact Julie Strandberg, Executive Director, at 775-688-1921 or chirobd@chirobd.nv.gov.

Members of the public that require special accommodations or assistance at the meetings must notify the Board office 48 hours prior to the meeting date.

Note: "A request for notice lapses 6 months after it is made": NRS 241.020.3(b). Mailing a copy of the Chiropractic Physicians' Board meeting agendas will not be continued unless a request for reinstatement on the mailing list is submitted in writing every 6 months.

AGENDA ACTION SHEET

TITLE: Agenda Item 1 Public Interest Comments - No action.

- A. Public Comment will be taken at the beginning and at the end of each Board meeting;
- B. Public Comment may also be taken at other such times as requested so long as the request that Public Comment be taken will not interrupt ongoing Board business;
- C. Depending on the number of individuals wishing to address the Board, a reasonable time limit may be set. The Board will not restrict comments based upon viewpoint;
- D. No action may be taken upon a matter raised during Public Comment until the matter itself has been specifically included on an agenda as an item upon which action may be taken.
- E. Prior to the commencement and conclusion of a contested case or a quasi-judicial proceeding that may affect the due process rights of an individual the Board may refuse to consider public comment as per NRS 233B.126.

RECOMMENDED M	MOTION: Non-Action item.
PRESENTED BY:	Margaret Colucci, DC
MEETING DATE:	January 14, 2021
TIME REQUIRED:	3 minutes per person per topic
BACKGROUND INFORMATION: The public may speak to the Board about any topic not on the agenda but no action may be taken.	
REVIEWED BY:	X President X Secretary X Executive Director
ACTION:App	rovedApproved w/ModificationsDenied Continued

AGENDA ACTION SHEET

The Board more items	m 2 Approval of Agenda reserves the right to ad s to accomplish busine rom the agenda or disc	ldress items in a di ss in the most eff	ifferent order (icient manner.	An item may be
RECOMMENDED N	MOTION: No recommen	ndation.		
PRESENTED BY:	Margaret Colucci, DC	1		
MEETING DATE:	January 14, 2021			
TIME REQUIRED:	2 minutes			
BACKGROUND IN accommodate those	FORMATION: Agenda present.	items may be addr	ressed out of or	der to
REVIEWED BY:	X President X	Secretary <u>X</u>	_Executive Dir	rector
ACTION: App	proved Approved w	/Modifications	Denied	Continued

AGENDA ACTION SHEET

11 LE: Agenda Item 3 Approval of the October 15, 2020 Meeting Minutes For possible action
RECOMMENDED MOTION: Approve the minutes of the October 15, 2020 meeting as drafted.
PRESENTED BY: Margaret Colucci, DC
MEETING DATE: January 14, 2021
TIME REQUIRED: 5 minutes
BACKGROUND INFORMATION:
REVIEWED BY: X President X Secretary X Executive Director
ACTION:ApprovedApproved w/ModificationsDenied Continued

Steve Sisolak
Governor

Margaret Colucci, DC
President
Nicole Canada, DC
Vice President
James T. Overland Sr., DC
Secretary-Treasurer



Morgan Rovetti, DC

Member

Xavier Martinez, DC

Member

Tracy DiFillippo, Esq.

Consumer Member

John Bertoldo, Esq.

Consumer Member

Julie Strandberg
Executive Director

CHIROPRACTIC PHYSICIAN'S BOARD OF NEVADA

4600 Kietzke Lane, M-245 | Reno, Nevada 89502-5000 Phone: (775) 688-1921 | Fax: (775) 688-1920

Website: http://chirobd.nv.gov | Email: chirobd@chirobd.nv.gov

MEETING MINUTES

A meeting of the Chiropractic Physicians' Board was held on Thursday, October 15, 2020 by zoom conference.

The following Board members were present at roll call:

Margaret Colucci, DC, President Nicole Canada, DC, Vice President James T. Overland Sr., DC, Secretary-Treasurer Morgan Rovetti, DC, Member Xavier Martinez, DC, Member John Bertoldo, Esq., Consumer Member

Also present were Board Counsel, Louis Ling, Esq. and Executive Director, Julie Strandberg.

President, Dr. Colucci determined a quorum was present and called the meeting to order.

Dr. Martinez led those present in the Pledge of Allegiance. Dr. Canada stated the Purpose of the Board.

Agenda Item 1 Public Interest Comments - No action.

Dr. Dave Rovetti stated that he had concerns with some of the agenda items. Dr. John Brown stated that the Nevada Chiropractic Council has contracted with the Chiropractic Therapy Assistant and directed the Board to the link on the Nevada Chiropractic Council's website.

Agenda Item 6 Legislative Matters – For possible action.

Dan Musgrove with Strategies 360 was present and provided an overview of what is happening on the legislative front. Mr. Musgrove also confirmed that the Boards' bill draft request (BDR) will be sponsored by Mr. Steve Yeager.

Mr. Ling stated that he spoke with Dr. Overland regarding the possibility of a CBD bill being introduced during the 2021 legislative session and requested that the sponsors of the bill(s) be contacted to request that Chiropractic be included in the bill.

Agenda Item 2 Approval of agenda – For possible action.

Dr. Canada moved to approve the agenda. Mr. Bertoldo seconded, and the motion passed with all in favor.

Dr. Overland asked why the associations were not on the agenda. Julie Strandberg stated that it was understood that unless a request was received in writing the associations would not be a standing agenda item, but comments could be made during public comment.

Agenda Item 3 Approval of the July 9, 2020 Board Meeting Minutes. - For possible action.

Dr. Overland moved to approve the July 9, 2020 meeting minutes. Dr. Canada seconded, and the motion passed with all in favor.

<u>Agenda Item 4</u> Ratification of granting of DC licenses to applicants who passed the examination from July to September 2020 – For possible action.

Dr. Martinez moved to approve the ratification of granting of DC licenses to those who passed the examination from July to September 2020. Dr. Overland seconded, and the motion passed with all in favor.

<u>Agenda Item 5</u> Ratification of granting of CA certificates to applicants who passed the inperson examination on August 25, 2020 – For possible action.

Dr. Canada moved to approve the ratification of granting of CA certificates to those who passed the in-person examination on August 25, 2020. Dr. Martinez seconded, and the motion passed with all in favor.

<u>Agenda Item 10</u> – Potential hearing or discussion of possible action in the Matter of Daniel Camilleri, DC, License No. B01553, Complaint No. 19-14N – For possible action (Note: The Board may go into closed session pursuant to NRS 241 to consider the character alleged misconduct, or professional competence of Dr. Camilleri.)

Dr. Camilleri and his attorney, Phillip Tiberi, were present. Mr. Ling introduced himself and gave the Board an overview of the complaint and the Settlement Agreement and Order. Following discussion, Dr. Martinez recommended that the Settlement Agreement and Order be approved. Mr. Bertoldo made a motion to approve the Settlement Agreement and Order. Dr. Canada seconded, and the motion passed with all in favor. Dr. Martinez recused himself as the investigating board member.

<u>Agenda Item 7</u> PUBLIC WORKSHOP: Will begin at 9:30 a.m. via Zoom videoconference. Discussion to consider amendments to Nevada Administrative Code 634. – For possible action.

Dr. Colucci opened the public workshop. Mr. Ling provided an overview of the recommended revisions to NAC 634. Dr. Colucci called for public comments. Following comments and clarification, Dr. Canada moved to approve the revisions to NAC 634. Dr. Overland seconded, and the motion passed with all in favor.

<u>Agenda Item 8</u> – Consideration/decision related to the application for CA Certificate for Jessica Olivares – For possible action (Note: The Board may go into closed session pursuant to NRS 241 to consider the character alleged misconduct, or professional competence of Ms. Olivares.)

Ms. Olivares was present and accepted to move into closed session. Mr. Bertoldo made a motion to move into closed session. Dr. Overland seconded, and the motion passed with all in favor. Julie Strandberg provided an overview of Ms. Olivares' appearance. Ms. Oliveras explained her reason for not answering affirmatively to questions regarding her background. Following questions from the Board, Dr. Colucci opened the meeting to the public. Dr. Rovetti made a motion to deny Ms. Olivares' application for chiropractor's assistant. Dr. Martinez seconded, and the motion passed with all in favor.

<u>Agenda Item 9</u> – Potential hearing or discussion of resolution and possible action in the Matter of Michael Milman, DC, License No. B01618, Complaint No. 20-07S – For possible action (Note: The Board may go into closed session pursuant to NRS 241 to consider the character alleged misconduct, or professional competence of Dr. Milman.)

Dr. Colucci announced that she is the investigating board member for complaint 20-07S and turned the chair over to Dr. Canada, Vice President to open the hearing in the matter of Dr. Michael Milman. Mr. Louis Ling, Board Counsel, Mr. Kevin Murphy, on behalf of Dr. Milman, Dr. Michael Milman, and Mr. Justin Taruc, Deputy Attorney General announced themselves.

Mr. Ling identified the items included in the Board packet that he and Mr. Murphy agreed would be stipulated into the record on this matter. Mr. Ling provided the Board with an overview of Dr. Milman's felony charge and disciplinary history in California where his chiropractic license was revoked. Mr. Ling stated that there are four causes of action. Mr. Ling explained that Dr. Milman is not here to contest these charges, but answer questions from the Board. Mr. Ling stated that the investigating board member, Dr. Colucci recommended that the Board parallel the California Board action by revoking Dr. Milman's license, based on how the Board has historically disciplined and impose fees and costs.

Mr. Murphy stated on behalf of Dr. Milman, that they are here to ask this body to address the criminal conduct that occurred between June 26 and November 20, 2013. Mr. Murphy continued by providing the Board with Dr. Milman's criminal preceding's as well as an overview of Dr. Milman's professional career.

Dr. Michael Milman was sworn in and Mr. Ling stipulated Dr. Olga testifying to Dr. Milman's character.

Dr. Milman began his testimony with questions from his attorney, Mr. Murphy.

Mr. Ling stated that he did not have any cross-examination questions for Dr. Milman.

Questioning was opened up to the Board to ask of Dr. Milman.

Mr. Taruc, DAG called for closing arguments.

Mr. Ling stated that he appreciated Mr. Murphy's professional courtesy in getting the Board to the issue as quickly as possible and allowing the Board to discuss their concerns with Dr. Milman directly. Mr. Ling recommended that the Board not find Dr. Milman in violation of not notifying the Board of his criminal charge identified in the fourth cause of action since based on Dr. Milman's testimony he did notify the Board on his 2018 self-inspection.

Mr. Murphy gave his closing argument clarifying Dr. Milman's position.

Dr. Rovetti made a motion to find the alleged four causes of action proven with the exception of the allegation in the fourth cause to disclose the criminal conviction. Dr. Overland seconded, and the motion passed with all in favor. Dr. Colucci recused herself as the investigating board member.

Dr. Rovetti made a motion that a five-year probation be imposed on Dr. Milman's license, assign a practice monitor, Board costs and attorney fees, take and pass the NBCE EBAS, cash only practice, no billing insurance or personal injury. Mr. Bertoldo seconded, and the motion failed three to two. Dr. Colucci recused herself as the investigating board member.

Dr. Rovetti made a motion to allow Dr. Milman to continue practicing with the following stipulations: impose five-years of probation on his license, with a practice monitor for five years at the cost of Dr. Milman, Board costs and attorney fees, take and pass the NBCE Ethics and Boundaries Assessment, carry the minimum malpractice insurance coverage, obtain the appropriate business licensure in the State of Nevada, cash only practice, with no billing of insurance and no personal injury cases. Mr. Bertoldo seconded, and the motion passed with the exception of Dr. Canada who opposed. Dr. Colucci recused herself as the investigating board member.

<u>Agenda Item 11</u> Consideration of including the supervising chiropractic physicians' signature on the Chiropractor's Assistant application – For possible action.

Julie Strandberg explained that an active DC submitted a request, in writing, to propose adding the signature of the CA's supervising chiropractic physician on the application. Following discussion, other concerns surfaced. Dr. Rovetti moved to table this agenda item. Dr. Martinez seconded, and the motion passed with all in favor.

<u>Agenda Item 12</u> Consideration of request by Jennifer Mamola to have credits from Truckee Meadows Community College counted towards her training as a chiropractor's assistant pursuant to NAC 634.355 (4) (b) – For possible action.

Julie Strandberg explained that Ms. Mamola submitted her CA application along with her transcript in accordance with NAC 634.355 (4) (b). Following discussion, Dr. Rovetti recommended that the Board set guidelines in order to provide consistency for review and approval of transcripts submitted by CA's. Mr. Bertoldo moved to not consider this request. Dr. Canada seconded, and the motion passed with all in favor.

Agenda Item 13 Board Counsel Report - No action.

Mr. Ling stated that he did not have anything to report.

<u>Agenda Item 15</u> Consideration of potential policies or guidance to Board staff – For possible action.

- A. Applicants who have had their license revoked, surrendered, etc. in another state be required to come into compliance in that state prior to approving their application.
 - Dr. Overland recommended that a policy not be required.
- B. Discipline for failing to submit Self-Inspection by March 31.

There were motions made recommending a fine between \$100.00 to \$350.00, however the motions failed. Following discussion, Dr. Canada moved to table this agenda item. Dr. Colucci seconded, and the motion passed with all in favor.

Agenda Item 14 Status report regarding anonymous profiles of possible disciplinary actions. Board action will be limited to either dismissing the matter if the Board determines there is no violation, it has no jurisdiction over the subject, or providing direction to pursue the matter further – For possible action:

A. Complaint 17-28S (Colucci)

Mr. Ling stated that a citation will be issued to the DC.

B. Complaint 18-13S (Rovetti)

Dr. Rovetti reported that this complaint is still under investigation.

C. Complaint 18-15S (Canada)

Dr. Canada stated that this complaint, 18-17S and 19-03S are against the same DC and is still under investigation.

D. Complaint 18-17S (Canada)

Dr. Canada stated that this complaint, 18-15S and 19-03S are against the same DC and is still under investigation.

E. Complaint 19-03S (Canada)

Dr. Canada stated that this complaint, 18-15S and 18-17S are against the same DC and is still under investigation.

F. Complaint 19-11S (Colucci)

Dr. Colucci stated that Dr. Stanley fulfilled his obligation of the citation by paying the fine, so this complaint is now closed.

G. Complaint 19-12S (Rovetti)

Dr. Rovetti confirmed that the allegations of this complaint do not concern public safety, but concern money issues within the office and reported that civil and criminal litigation are currently in progress. Dr. Rovetti stated that following discussion with Mr. Ling it was determined to wait until those cases are resolved. Mr. Ling stated that he has been in touch with counsel who will provide updates.

H. Complaint 19-13N (Martinez)

Dr. Martinez stated that the complainant alleged unprofessional conduct and following an extensive investigation a letter of admonishment was issued and signed by the chiropractic physician. Dr. Martinez recommended dismissal of this complaint. Dr. Rovetti made a motion to dismiss complaint 19-13N. Dr. Overland seconded, and the motion passed with all in favor. Dr. Martinez recused himself as the investigating board member.

I. Complaint 19-14N (Martinez)

Dr. Martinez stated that the Settlement Agreement and Order against Dr. Camilleri was approved under agenda item 10.

J. Complaint 19-16S (Canada)

Dr. Canada stated that the complainant alleged that they paid an excessive amount of money for a treatment that did not help. However, when Dr. Canada visited the practice to speak with the DC, who was not available, she reminded the staff that the DC and CA wall certificates are required to be posted. Dr. Canada made a follow-up visit, one month later to find they were still out of compliance. Dr. Canada left a message for the chiropractic physician, but received no response. Dr. Canada recommended that the DC be fined. Mr. Ling confirmed that to propose a fine, the DC would need to be disciplined, so a citation would be issued.

K. Complaint 19-18N (Martinez)

Dr. Martinez stated that this complaint is against the same chiropractic physician as complaint 19-13N. Dr. Rovetti moved to dismiss complaint 19-18N. Mr. Bertoldo seconded, and the motion passed with all in favor. Dr. Martinez recused himself as the investigating board member.

L. Complaint 20-01N (Rovetti)

Dr. Rovetti reported that this complaint is still under investigation.

M. Complaint 20-03N (Rovetti)

Dr. Rovetti reported that this complaint is still under investigation.

N. Complaint 20-04N (Colucci)

Dr. Colucci stated that this is an anonymous complaint against a chiropractic physician with an expired license allegedly performing chiropractic. Dr. Colucci recommended dismissal unless the Board recommends additional investigation take place. Dr. Rovetti and Dr. Overland recommended that additional investigation be done.

O. Complaint 20-05S (Colucci)

Dr. Colucci stated that this is an anonymous complaint who was referred to the chiropractic physician following a car accident. Following an investigation, a citation was served for unlicensed chiropractors assistants.

P. Complaint 20-06S (Canada)

Dr. Canada stated that the complainant alleged that the chiropractic physician did not release their records timely and sold the lien to a 3rd party. Following an investigation, Dr. Canada reported that the records were provided and there were no other violations found, so she recommended that this complaint be dismissed. Dr. Overland made a motion to dismiss complaint 20-06S. Dr. Martinez seconded, and the motion passed with all in favor. Dr. Canada recused herself as the investigating board member.

Q. Complaint 20-07S (Colucci)

This complaint was the matter of Dr. Michael Milman discussed under agenda item 9.

R. Complaint 20-09S (Martinez)

Dr. Martinez stated that the complainant was in an auto accident and the chiropractic physician accepted the case on a lien basis. Following an investigation, once the complainant lost the case this became a financial dispute, which the Board does not get involved with, so Dr. Martinez recommended dismissal. Mr. Bertoldo made a motion to dismiss complaint 20-09S. Dr. Canada seconded, and the motion passed with all in favor. Dr. Martinez recused himself as the investigating board member.

S. Complaint 20-10S (Martinez)

Dr. Martinez stated that the complainant alleged injury and unprofessional conduct and is still under investigation.

T. Complaint 20-11S (Canada)

Dr. Canada stated that the complainant was in an auto accident and the DC accepted the case on a lien basis. Following investigation, once the complainant lost the case this became a financial dispute, which the Board does not get involved with, so Dr. Canada recommended dismissal. Dr. Martinez made a motion to dismiss complaint 20-09S. Mr. Bertoldo seconded, and the motion passed with all in favor. Dr. Canada recused herself as the investigating board member.

Agenda Item 16 Committee Reports

A. Continuing Education Committee (Dr. Martinez) – For possible action.

Dr. Martinez did not have anything new to report.

B. Legislative Committee (Dr. Colucci) – For possible action.

Dr. Colucci stated that Steve Yeager has agreed to sponsor the Boards bill.

C. Preceptorship Committee (Dr. Rovetti) – For possible action.

Dr. Rovetti stated that she recently completed supervising her first preceptor from Life West and indicated that due to COVID there may be more preceptors reaching out to practices due to the restrictions in place at the schools.

D. Test Committee (Dr. Canada) - For possible action.

1. CA communication

Dr. Overland stated that there was a discrepancy in the CA exam location between the CA's letter versus the location identified on the website, however nobody missed the test.

2. Set CA exam schedule

The CA exam dates for 2021 were scheduled as follows: February 16 (in-person & on-line); June 18 (on-line only); September 28 (in-person & on-line)

3. CA exam questions

Dr. Canada explained that she reviewed the most commonly missed questions, which she also found confusing, and revised those questions. Dr. Overland asked if the entire Board should revise questions rather than the individual who is on the test committee.

<u>Agenda Item 17</u> Discussion to extend the December 31, 2020 continuing education deadline for chiropractic physicians. – For possible action.

Dr. Rovetti stated that this agenda item is to request that the board extend the continuing education deadline. Dr. Rovetti explained that it is more effective to take in-person continuing education versus on-line.

Mr. Ling explained that it is not at the Boards' discretion to extend the continuing education deadline, since the Board cannot legally waive a statute. Mr. Ling stated that the only way that a statute can be waived is at the order of the Governor. Dr. David Rovetti stated that he spoke to the Physical Therapy Board, who referenced Emergency Directive 009, Section 3 that allows their licensees a 90-day forbearance. Mr. Ling confirmed that Directive 009, Section 3 was rescinded in Executive Directive 26 effective June 30, 2020.

Dr. Rovetti asked that if the Board were to extend the continuing education deadline, where would the backlash come from? Dr. Rovetti doesn't believe that the Governor would reprimand the Board for a one-time exception during a global pandemic and felt that the Board should take the steps to move this forward. Mr. Ling stated that since the Board does not require any in-person continuing education it is a tough argument to make.

<u>Agenda Item 18</u> Discussion regarding the notice of the continuing education audit on the license renewal/timing of the continuing education audit. – For possible action.

Dr. Rovetti recommended that the timing of the random continuing education audit follow the end of the license renewal period. Julie Strandberg asked if the Board had any recommendations on the timing. Dr. Canada recommended 30 days following the renewal deadline and allow 30 days to respond. Dr. Rovetti recommended that Julie Strandberg determine the timeframe and send a postcard to those who were selected.

Mr. Bertoldo announced that he had to leave the meeting.

Agenda Item 19 Discussion of the protocols to add an agenda item. – For possible action

Dr. Overland asked if there were protocols for items to be added to the Board meeting agenda and who approves the agenda? Julie Strandberg stated that at the previous Board meeting it was confirmed that a Board member may submit their request in writing, which is then forwarded to the Board President for review and final approval to be put on the agenda. If there is a concern, then a discussion would take place. Dr. Overland made a motion to table this agenda item and stated that he and Dr. Rovetti will prepare a policy to present at the next Board meeting. Dr. Rovetti seconded, and the motion passed with all in favor.

<u>Agenda Item 20</u> Discussion and approval regarding the policy pursuant to NRS 622.234 – For possible action.

- 1. Review and attestation by two or more Board members of each expenditure and the back-up of the expenditure.
- 2. Quarterly review by the board of the board's financial statements to include a schedule of the board's disbursements.

Mr. Ling stated that this legislation passed during the 2019 session to ensure Boards do not get embezzled by staff. Dr. Overland made a motion to adopt the legislature mandate for item #1 and #2. Dr. Martinez seconded, and the motion passed with all in favor. Dr. Canada and Dr. Overland will review the expenditures and backup each month.

Agenda Item 21 Executive Director Reports:

- A. Status of Pending Complaints No action.
- B. Status of Current Disciplinary Actions No action.
- C. Legal/Investigatory Costs No action.

 Julie Strandberg gave an overview of the executive director reports.

Agenda Item 22 Financial Status Reports:

- A. Current cash position & projections No action.
- B. Accounts Receivable Summary No action.
- C. Accounts Payable Summary No action.
- D. Employee Accrued Compensation No action.
- E. Income/Expense Actual to Budget Comparison No action.
- F. Budget to Actual No action.

Julie Strandberg gave an overview of the financial reports.

Agenda Item 23 Discussion and potential action regarding the Boards' 2021 meeting schedule - For possible action.

The 2021 Board meetings were scheduled as follows: January 14th, April 17th, July 15th, and October 16th.

Agenda Item 24 Public Interest Comments - No action.

This portion of the meeting is open to the public to speak on any topic NOT on today's agenda and may be limited to 3 minutes.

Dr. David Rovetti commented that the Board's financials will reach close to \$1 million following DC renewals and stated that the NCA may recommend a reduction to the renewal fees.

Dr. Martinez shared his concern with franchise group who advertises a wellness model. Dr. Martinez stated that during the course of an investigation he feels that from a public safety standpoint there is a potential risk, since there does not appear to be any oversight to this model.

Mr. Ling recommended that comments regarding facilities or chiropractic practices be held until the Board discusses its bill before the legislature.

Agenda Item 25 Adjournment – For possible action.

Dr. Overland moved to adjourn the meeting. Mr. Martinez seconded, and the motion passed unanimously

January 14, 2021

James T. Overland Sr., DC Secretary Treasurer

AGENDA ACTION SHEET

	ication of granting of DC licenses to applicants who passon October to December 2020 – For possible action	÷d
RECOMMENDED MOTION:	Ratify granting of DC licenses to those who passed the examinations from October to December 2020.	ir
PRESENTED BY: Margare	t Colucci, DC	
MEETING DATE: January	14, 2021	
TIME REQUIRED: 2 minute	s	
BACKGROUND INFORMATI	ON:	
October Shannon Beth Darrow, DC Kristina Renee Pellegrino, DC	November Kristen Diane Menchhofer, DC Lacey Nicole Venanzi, DC Kristin Victoria Hirai, DC Benjamin Jacob Adleburg, DC	
<u>December</u> Jessica Ruth McKelvey		
REVIEWED BY: X I	President X Secretary X Executive Director	
ACTION:Approved	Approved w/ModificationsDenied Continued	

AGENDA ACTION SHEET

	<u>n 5</u> Legislative Matters – For possible act s 360 - Dan Musgrove	ion
RECOMMENDED M	MOTION: No recommendation.	
PRESENTED BY:	Dan Musgrove	
MEETING DATE:	January 14, 2021	
TIME REQUIRED:	15 minutes	
BACKGROUND IN	FORMATION:	
REVIEWED BY:	X President X Secretary X	Executive Director
ACTION:Appr	rovedApproved w/Modifications	Denied Continued

AGENDA ACTION SHEET

TITLE: <u>Agenda Item 6</u> Discussion and possible action regarding CBD-containing products – For possible action.

RECOMMENDED N	IOTION: No recommendation.
PRESENTED BY:	James T. Overland Sr., DC
MEETING DATE:	January 14, 2021
TIME REQUIRED:	15 minutes
BACKGROUND IN	ORMATION:
REVIEWED BY:	X President X Secretary X Executive Director
ACTION:App	rovedApproved w/ModificationsDenied Continued

PROPOSED REGULATION OF THE STATE BOARD OF PHARMACY

LCB FILE NO. R090-20I

The following document is the initial draft regulation proposed by the agency submitted on 06/19/2020

Proposed Regulation of the Nevada State Board of Pharmacy

Workshop June 3, 2020

Explanation – Language in *blue italics* is new; language in *red text* [omitted material] is language to be omitted, and language in *green text* indicates prior Board-approved amendments that are in the process of being codified.

AUTHORITY: NRS 639.070 and NRS 453.146

A REGULATION relating to controlled substances; removing certain substances to the controlled substances listed in Schedule I and V; and providing other matters properly relating thereto.

Section 1. NAC 453.510 is hereby amended to read as follows:

453.510 1. Schedule I consists of the drugs and other substances listed in this section by whatever official, common, usual, chemical or trade name designated.

2. Unless specifically excepted or unless listed in another schedule, any of the following opiates, including, without limitation, their isomers, esters, ethers, salts and salts of isomers, esters and ethers, whenever the existence of such isomers, esters, ethers and salts is possible within the specific chemical designation:

Acetyl-alpha-methylfentanyl (N-[1-(1-methyl-2-phenethyl)-4-piperidinyl]-Nphenylacetamide);

Acetylmethadol;

Acryl fentanyl (N-(1-phenethylpiperidin-4-yl)-N-phenylacrylamide) (some trade or other names: Acryloylfentanyl);

Allylprodine;


Alphacetylmethadol (except levo-alphacetylmethadol, commonly referred to as levoalpha-acetylmethadol, levomethadyl acetate or "LAAM");

```
Alphameprodine;
Alphamethadol;
Alphamethylfentanyl (N-[1-(alpha-methyl-beta-phenyl)ethyl-4-piperidyl] propionanilide;
   1-(1-methyl-2-phenylethyl)-4-(N-propanilido) piperidine);
Alpha-methylthiofentanyl (N-[1-methyl-2-(2-thienyl)ethyl-4-piperidinyl]-N-
   phenylpropanamide);
Benzethidine;
Betacetylmethadol;
Beta-hydroxyfentanyl (N-[1-(2-hydroxy-2-phenethyl)-4-piperidinyl]-N-
   phenylpropanamide);
Beta-hydroxy-3-methylfentanyl (other name: N-[1-(2-hydroxy-2-phenethyl)-3-methyl-4-
   piperidinyl]-N-phenylpropanamide);
Beta-hydroxythiofentanyl (some other trade names: N-[1-[2-hydroxy-2-(thiophen-2-
   yl)ethyl]piperidin-4-yl]-N-phenylpropionamide; N-[1-[2-hydroxy-2-(2-thienyl)ethyl]-
   4-piperidinyl]-N-phenylpropanamide);
Betameprodine;
Betamethadol;
Betaprodine;
Butyryl fentanyl (some other trade names: N-(1-phenethylpiperidin-4-yl)-N-
phenylbutyramide; N-(1-phenethylpiperidin-4-yl)-N-phenylbutanamide);
Clonitazene;
Cyclopentyl fentanyl (N-(1-phenethylpiperidin-4-yl)-N-phenylcyclopentanecarboxamide);
```

```
Cyclopropyl fentanyl (N-(1-phenethylpiperidin-4-yl)-N-
   phenylcyclopropanecarboxamide);
Dextromoramide;
Diampromide;
Diethylthiambutene;
Difenoxin;
Dimenoxadol;
Dimepheptanol;
Dimethylthiambutene;
Dioxaphetyl butyrate;
Dipipanone;
Ethylmethylthiambutene;
Etonitazene;
Etoxeridine;
4-Fluoroisobutyryl fentanyl (N-(4-fluorophenyl)-N-(1-phenethylpiperidin-4-
   yl)isobutyramide) (some trade or other names: Para-fluoroisobutyryl fentanyl);
Furanyl fentanyl (N-(1-phenethylpiperidin-4-yl)-N-phenylfuran-2-carboxamide);
Furethidine;
Hydroxypethidine;
Isobutyryl fentanyl (N-(1-phenethylpiperidin-4-yl)-N-phenylisobutyramide);
Ketobemidone;
Levomoramide;
Levophenacylmorphan;
```

```
3-Methylfentanyl (N-[3-methyl-1-(2-phenylethyl)-4-piperidyl]-N-phenylpropanamide);
3-Methylthiofentanyl (N-[(3-methyl-1-(2-thienyl)ethyl-4-piperidinyl]-N-
   phenylpropanamide);
Methoxyacetyl fentanyl (2-methoxy-N-(1-phenethylpiperidin-4-yl)-N-phenylacetamide);
Morpheridine;
MPPP (1-methyl-4-phenyl-4-propionoxypiperidine);
Noracymethadol;
Norlevorphanol;
Normethadone;
Norpipanone;
Ocfentanil (N-(2-fluorophenyl)-2-methoxy-N-(1-phenethylpiperidin-4-yl)acetamide
Para-chloroisobutyryl fentanyl (N-(4-chlorophenyl)-N-(1-phenethylpiperidin-4-
   yl)isobutyramide);
Para-fluorofentanyl (N-(4-fluorophenyl)-N-[1-(2-phenethyl)-4-piperidinyl]propanamide);
Para-fluorobutyryl fentanyl (N-(4-fluorophenyl)-N-(1-phenethylpiperidin-4-
   yl)butyramide);
Para-methoxybutyryl fentanyl (N-(4-methoxyphenyl)-N-(1-phenethylpiperidin-4-
   yl)butyramide);
PEPAP (1-(-2-phenethyl)-4-phenyl-4-acetoxypiperidine);
Phenadoxone;
Phenampromide;
Phenomorphan;
Phenoperidine;
```

	Piritramide;
	Proheptazine;
	Properidine;
	Propiram;
	Racemoramide;
	$Tetrahydrofuranyl\ (N-(1-phenethylpiperidin-4-yl)-N-phenyltetrahydrofuran-2-yl)-N-phenyltetrahydrofuran-2-yl-n-phenyltetrahydrofuran-1-yl-n-phenyltetrahydrofuran-2-yl-n-phenyltetrahydrofuran-2-yl-n-phenyltetrahydrofuran-1-yl-n-phenyltetrahydrofuran-2-yl-n-phenyltetrahydrofuran-1-yl-n-phenyltetrahydrofur$
	carboxamide);
	Thiofentanyl (N-phenyl-N-[1-(2-thienyl)ethyl-4-piperidinyl]-propanamide);
	Tilidine; or
	Trimeperidine.
	Valeryl fentanyl (N-(1-phenethylpiperidin-4-yl)-N-phenylpentanamide);
3.	Unless specifically excepted or unless listed in another schedule, any of the following
opium	derivatives, including, without limitation, their salts, isomers and salts of isomers,
whene	ever the existence of such salts, isomers and salts of isomers is possible within the specific
chemic	cal designation:
	Acetorphine;
	Acetyldihydrocodeine;
	Acetylfentanyl;
	Benzylmorphine;
	Codeine methylbromide;
	Codeine-N-Oxide;
	Cyprenorphine;
	Desomorphine;



compound, mixture or preparation which contains any quantity of the following hallucinogenic substances, including, without limitation, their salts, isomers and salts of isomers, whenever the existence of such salts, isomers and salts of isomers is possible within the specific chemical designation:

Alpha-ethyltryptamine (some trade or other names: ET, Trip);

Alpha-methyltryptamine (some trade or other names: AMT);

- 1,4-Butanediol (some trade or other names: 1,4-butyleneglycol, dihydroxybutane, tetramethylene glycol, butane 1,4-diol, SomatoPro, Soma Solutions, Zen);
- 4-bromo-2,5-dimethoxyamphetamine (some trade or other names: 4-bromo-2,5-dimethoxy-alpha-methylphenethylamine; 4-bromo-2,5-DMA);
- 4-bromo-2,5-dimethoxyphenethylamine (some trade or other names: Nexus, 2C-B);
- 1-Butyl-3-(1-naphthoyl)indole-7173 (some trade or other names: JWH-073);
- 2-(4-Chloro-2,5-dimethoxyphenyl)ethanamine (some trade or other names: 2C-C);
- 4-(2-chlorophenyl)-2-ethyl-9-methyl-6H-thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepine (some trade or other names: Etizolam);
- 1-cyclohexylethyl-3-(2-methoxyphenylacetyl)indole (some trade or other names: SR-18; BTM-8; RCS-8);
- 2,5-dimethoxyamphetamine (some trade or other names: 2,5-dimethoxy-alphamethylphenethylamine; 2,5-DMA);
- 2,5-dimethoxy-4-ethylamphet-amine (some trade or other names: DOET);
- 2-(2,5-Dimethoxy-4-ethylphenyl)ethanamine (some trade or other names: 2C-E);
- 2-(2,5-Dimethoxy-4-methylphenyl)ethanamine (some trade or other names: 2C-D);
- 2-(2,5-Dimethoxy-4-nitro-phenyl)ethanamine (some trade or other names: 2C-N);
- All 2,5-Dimethoxy-N-(2-methoxybenzyl) phenethylamine (NBOMe) and any derivatives thereof (some trade or other names: 2C-X-NBOMe; N-benzylated phenethylamines; N-o-methoxybenzyl analogs; NBOMe; 25H-NBOMe; 25B-NBOMe; 25C-BOMe; 25D-NBOMe; 25E-NBOMe; 25I-NBOMe; 25N-NBOMe; 25P-NBOMe; 25T2-NBOMe; 25T4-NBOMe; 25T7-NBOMe)
- 2-(2,5-Dimethoxy-4-(n)-propylphenyl)ethanamine (some trade or other names: 2C-P);

- 2,5-dimethoxy-4-(n)-propylthiophenethylamine (some trade or other names: 2C-T-7);
- 2-(2,5-Dimethoxyphenyl)ethanamine (some trade or other names: 2C-H);
- 3-[2-(Dimethylamino)ethyl]-1H-indol-4-yl acetate (some trade or other names: 4-acetoxy-N,N-dimethyltryptamine; 4-AcO-DMT; psilacetin; O-acetylpsilocin; 4-acetoxy-DMT)
- 5-(1,1-Dimethylheptyl)-2-[(1R,3S)-3-hydroxycyclohexyl]-phenol-7297 (some trade or other names: CP-47,497);
- 5-(1,1-Dimethyloctyl)-2-[(1R,3S)-3-hydroxycyclohexyl]-phenol-7298 (some trade or other names: cannabicyclohexanol; CP-47,497 C8 homologue);
- Ethyl 2-(1-(5-fluoropentyl)-1H-indazole-3-carboxamido)-3,3-dimethylbutanoate (some trade or other names: 5F-EDMB-PINACA);
- 4-ethylnaphthalen-1-yl-(1-pentylindol-3-yl)methanone (some trade or other names: (4-ethyl-1-naphthalenyl)(1-pentyl-1H-indol-3-yl)-methanone; JWH-210);
- 2-[4-(Ethylthio)-2,5-dimethoxyphenyl]ethanamine (some trade or other names: 2C-T-2);
- (1-(4-fluorobenzyl)-1H-indol-3-yl)(2,2,3,3-tetramethylcyclopropyl)methanone (some trade or other names: FUB-144);
- 2-(1-(4-fluorobenzyl)-1H-indazole-3-carboxamido)-3-methylbutanoate (Some trade or other names: FUB-AMB; MMB-FUBINACA);
- [1-(5-fluoropentyl)-1H-indazol-3-yl](naphthalen-1-yl)methanone (some trade or other names: THJ-2201; 5-fluoro THJ 018; AM2201 indazole analog; fluorpentyl JWH 018 indazole);
- [1-(5-fluoropentyl)-1H-indol-3-yl]-1-naphthalenyl-methanone (some trade or other names: 1-(5-fluoropentyl)-3-(1-naphthoyl)indole; AM-2201);

- [1-(5-fluoropentyl)-1H-indol-3-yl]-(2-iodophyenyl)-methanone (some trade or other names: 1-(5-fluoropentyl)-3-(2-iodobenzoyl)indole; AM-694);
- (1-(5-fluoropentyl)-1H-indol-3-yl)(2,2,3,3-tetramethylcyclopropyl)methanone (some trade or other names: XLR-11);
- 1-(5-fluoropentyl)-N-(2-phenylpropan-2-yl)-1H-indazole-3-carboxamide (some trade or other names: 5F-CUMYL-PINACA; SGT-25);
- 1-(5-fluoropentyl)-N-(tricyclo[3.3.1.13,7]dec-1-yl)-1H-indazole-3-carboxamide (some trade or other names: N-((3s,5s,7s)-adamantan-1-yl)-1-(5-fluoropentyl)-1H-indazole-3-carboxamide; APINACA 5-fluoropentyl analog; 5F-AKB48; 5-Fluoro-AKB48; 5F-APINACA; 5-Fluoro-APINACA)
- 1-(5-fluoropentyl)-8-quinolinyl ester-1H-indole-3-carboxylic acid (some trade or other names: 1-(5-fluoropentyl)-1H-indole-3-carboxylic acid 8-quinolinyl ester; 5-Fluoro-PB-22; 5F-PB-22)
- 2-(4-Iodo-2,5-dimethoxyphenyl)ethanamine (some trade or other names: 2C-I);
- 2-[4-(Isopropylthio)-2,5-dimethoxyphenyl]ethanamine (some trade or other names: 2C-T-4);
- 1-hexyl-3-(1-naphthoyl)indole (some trade or other names: JWH-019);
- 4-methoxyamphetamine (some trade or other names: 4-methoxy-alphamethylphenethylamine; para-methoxyamphetamine; PMA);
- (4-methoxy-1-naphthalenyl)(1-pentyl-1H-indol-3-yl)-methanone (some trade or other names: JWH-081);
- 5-methoxy-3,4-methylenedioxyamphetamine (some trade or other names: MMDA);
- 5-methoxy-N, N-diisopropyltryptamine (some trade or other names: 5-meO-DIPT);

- 4-methyl-2,5-dimethoxyamphetamine (some trade or other names: 4-methyl-2,5-dimethoxy-alpha-methylphenethylamine; "DOM"; "STP");
- (4-methyl-1-naphthalenyl)(1-pentyl-1H-indol-3-yl)-methanone (some trade or other names: JWH-122);
- Methyl 2-(1-(5-fluoropentyl)-1H-indazole-3-carboxamido)-3,3-dimethylbutanoate (some trade or other names: 5F-ADB; 5F-MDMB-PINACA);
- Methyl 2-(1-(5-fluoropentyl)-1H-indole-3-carboxamido)-3,3-Dimethylbutanoate (some trade or other names: 5F-MDMB-PICA);
- [3,4 m] Methylenedioxyamphetamine (some trade or other names: MDA);
- [3,4-m] Methylenedioxymethamphetamine (MDMA);
- [3,4-m]Methylenedioxy-N-ethylamphetamine (commonly referred to as N-ethyl-alphamethyl-3,4(methylenedioxy) phenethylamine, N-ethyl MDA, MDE, MDEA);
- 1-[2-(4-Morpholinyl)ethyl]-3-(1-naphthoyl)indole-7200 (some trade or other names: JWH-200);
- N-(adamantan-1-yl)-1-(4-fluorobenzyl)-1H-indazole-3-carboxamide (some trade or other names: FUB-AKB48; FUB-APINACA; AKB48 N-(4-fluorobenzyl);
- N-(1-adamantyl)-1-pentyl-1H-indazole-3-carboxamide (some trade or other names: 1-pentyl-N-tricyclo[3.3.1.13,7]dec-1-yl-1H-indazole-3-carboxamide; APINACA; AKB48)
- N-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)1-(cyclohexylmethyl)-1H-indazole-3-carboxamide (some trade or other names: ADB-CHMINCA or MAB-CHMINACA)
- N-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-1-pentyl-1H-indazole-3-carboxamide (some trade or other names: ADB-PINACA)

- N-(1-amino-3-methyl-1-oxobutan-2-yl)-1-pentyl-1H-indazole-3-carboxamide (some trade or other names: AB-PINACA);
- N-(1-amino-3-methyl-1-oxobutan-2-yl)-1-(4fluorobenzyl)-1H-indazole-3-carboxamide (some trade or other names: AB-FUBINACA)
- N-[(1S)-1-(aminocarbonyl)-2-methylpropyl]-1-(cyclohexylmethyl)-1H-indazole-3-carboxamide (some trade or other names: AB-CHMINACA)
- N-hydroxy-3,4-methylenedioxyamphetamine (commonly referred to as N-hydroxy-alphamethyl-3,4(methylenedioxy) phenethylamine, N-hydroxy MDA);
- 2-(2-methoxyphenyl)-1-(1-pentylindol-3-yl)ethanone (some trade or other names: 1-(1-pentyl-1H-indol-3-yl)-2-(2-methoxyphenyl)-ethanone; 1-pentyl-3-(2-methoxyphenylacetyl)indole; JWH-250);
- 1-Pentyl-3-(2-chlorophenylacetyl)indole (some trade or other names: JWH-203);
- 1-Pentyl-3-(4-cholor-1-naphthoyl)indole (some trade or other names: JWH-398);
- 1-Pentyl-3-[(4-methoxy)-benzoyl]indole (some trade or other names: SR-19; BTM-4; RCS-4);
- 1-Pentyl-3-(1-naphthoyl)indole-7118 (some trade or other names: JWH-018; AM678);
- (1-pentylindol-3-yl)-(2,2,3,3-tetramethylcyclopropyl)methanone (some trade or other names: UR-144);
- 1-pentyl-N-(tricyclo[3.3.1.1 ^{3,7}]dec-1-yl-1H-indole-3 carboxamide (some trade or other names: APICA; JWH-018 adamantyl carboxamide; 2NE1; SDB-001);
- 1-pentyl-8-quinolinyl ester-1H-indole-3-carboxylic acid (some trade or other names: 1- pentyl-1H-indole-3-carboxylic acid 8-quinolinyl ester; PB-22; QUPIC)
- 3,4,5-trimethoxyamphetamine;

Bufotenine (some trade or other names: 3-(beta-dimethylaminoethyl)-5-hydroxyindole; 3-(2-dimethyl-aminoethyl)-5-indolol; N, N-dimethylserotonin; 5-hydroxy-N, N-dimethyltryptamine; mappine);

Diethyltryptamine (some trade or other names: DET; N,N-Diethyltryptamine);

Dimethyltryptamine (some trade or other names: DMT; N,N-DMT; N,N-Dimethyltryptamine);

Fluorophenylpiperazine (some trade or other names: FPP, pFPP, 2-fluorophenylpiperazine, 3-fluorophenylpiperazine, 4-fluorophenylpiperazine);

Gamma butyrolactone (some trade or other names: GBL, Gamma Buty Lactone, 4-butyrolactone, dihydro-2(3H)-furanone, tetrahydro-2-furanone, Gamma G, GH Gold);

Gamma hydroxy butyric acid (some trade or other names: GHB);

Ibogaine (some trade or other names: 7-ethyl-6, 6 beta, 7, 8, 9, 10, 12, 13-octahydro-2-methoxy-6, 9-methano-5H-pyrido (1',2':1,2) azepino (5,4-b) indole; Tabernanthe iboga);

Lysergic acid diethylamide;

Marijuana;

Mescaline;

Methoxyphenylpiperazine (some trade or other names: MeOPP, pMPP, 4-MPP, 2-MeOPP, 3-MeOPP, 4-MeOPP);

Parahexyl (some trade or other names: 3-Hexyl-1-hydroxy-7, 8, 9, 10-tetrahydro-6,6,9-trimethyl-6H-dibenzo[b,d]pyran; Synhexyl);

Peyote (meaning all parts of the plant presently classified botanically as Lophophora williamsii Lemaire, whether growing or not, the seeds thereof, any extract from any

```
part of such plant, and every compound, manufacture, salts, derivative, mixture, or
          preparation of such plant, its seeds or extracts);
       N-benzylpiperazine (some trade or other names: BZP, 1-benzylpiperazine);
       N-ethyl-3-piperidyl benzilate;
       N-methyl-3-piperidyl benzilate;
       Psilocybin;
       Psilocin;
       Salvinorin A (some trade or other names: Divinorin A; Methyl
          (2S,4aR,6aR,7R,9S,10aS,10bR)-9-(acetyloxy)-2-(furan-3-yl)-6a,10b-dimethyl-4,10-
          dioxododecahydro-2H-benzo[f]isochromene-7-carboxylate);
       Ethylamine analog of phencylidine (some trade or other names: N-ethyl-1-
          phenylcyclohexylamine; (1-phenylcyclohexyl) ethylamine; N-(1-phencyclohelyl)
          ethylamine; cyclohexamine; PCE);
       Pyrrolidine analog of phencyclidinde (some trade or other names: 1-1(1-
          phenylcyclohexyl)-pyrrolidine; PCPy; PHP);
       1-(1-(2-thienyl)-cyclohexyl)-pyrrolidine (some trade or other names: TCPy);
       Thiophene analog of phencyclidine (some trade or other names: 1-(1-(2-thienyl)-
          cyclohexyl)-piperidine; 2-thienyl analog of phencyclidine; TPCP; TCP); or
       Trifluoromethylphenylpiperazine (some trade or other names: 1-(3-
          trifluoromethylphenyl)piperazine; 3-trifluoromethylphenylpiperazine; TFMPP)
→ For the purposes of this subsection, "isomer" includes, without limitation, the optical, position
or geometric isomer.
```

- 5. All parts of the plant presently classified botanically as Datura, whether growing or not, the seeds thereof, any extract from any part of such plant or plants, and every compound, manufacture, salt derivative, mixture or preparation of such plant or plants, its seeds or extracts, unless substances consistent with those found in such plants are present in formulations that the Food and Drug Administration of the United States Department of Health and Human Services has approved for distribution.
- 6. Unless specifically excepted or unless listed in another schedule, any material, compound, mixture or preparation which contains any quantity of phencyclidine, mecloqualone or methaqualone having a depressant effect on the central nervous system, including, without limitation, their salts, isomers and salts of isomers, whenever the existence of such salts, isomers and salts of isomers is possible within the specific chemical designation.
- 7. Unless specifically excepted or unless listed in another schedule, any material, compound, mixture or preparation which contains any quantity of the following substances having a stimulant effect on the central nervous system, including, without limitation, their salts, isomers and salts of isomers:

Alpha-pyrrolidinoheptaphenone (some trade or other names: PV8);

Alpha-pyrrolidinohexanophenone (some trade or other names: Alpha-PHP);

Alpha-PBP (some trade or other names: 1-phenyl-2-(pyrrolidine-1-yl)butan-1-one, alpha-pyrrolidinobutiophenone);

Alpha-PVP (some trade or other names: 1-phenyl-2-(1-pyrrolidinyl)-1-pentanone, alpha-pyrrolidinopentiophenone, alpha-pyrrolidinovalerophenone, O-2387);

Aminorex;

```
Butylone (some trade or other names: 1-(1,3-benzodioxol-5-yl)-2-(methylamino)butan-1-
   one, β-keto-N-methylbenzodioxolylpropylamine, bk-MBDB);
Cathinone (some trade or other names: 2-amino-1-phenyl-1-propanone; alpha-
   aminopropiophenone; 2-aminopropiophenone; norephedrone);
4-chloro-alpha-pyrrolidinovalerophenone (some trade or other names: 4-chloro-a-PVP);
Dimethylone (some trade or other names: 3,4-methylenedioxy-N,N-dimethylcathinone;
   N,N-dimethyl MDCATH; N,N-dimethyl-3,4-methylenedioxycathinone; N,N-
   dimethyl-β-keto-3,4-methylenedioxyamphetamine; 1-(1,3-benzodioxol-5-yl)-2-
   (dimethylamino)propan-1-one; bk-MDDMA)
N-ethylhexedrone;
Ethylone (some trade or other names: N-ethyl-3,4-methylenedioxycathinone; 1-(1,3-
   benzodioxol-5-yl)-2-(ethylamino)propan-1-one; MDEC; bk-MDEA)
N-ethylpentylone (1-(1,3-benzodioxol-5-yl)-2-ethylamino)-pentan-1-one) (some trade or
   other names: Ephylone);
Fenethylline;
Fluoroamphetamine (some trade or other names: 2-fluoroamphetamine, 3-
   fluoroamphetamine, 4-fluoroamphetamine, 2-FA, 3-FA, 4-FA, PFA);
Fluoromethcathinone (some trade or other names: 4-Fluoro-N-methylcathinone, 1-(4-
```

Fluoromethcathinone (some trade or other names: 4-Fluoro-N-methylcathinone, 1-(4-fluorophenyl)-2-(methylamino)propan-1-one, 4-Fluoromethcathinone (Flephedrone), 4-FMC, 3-Fluoro-N-methylcathinone, 1-(3-fluorophenyl)-2-2(methylamino)propan-1-one, 3-Fluoromethcathinone, 3-FMC, 2-Fluoro-N-methylcathinone, 1-(2-fluorophenyl)-2-(methylamino)propan-1-one, 2-FMC);

4-methyl-alpha-ethylaminopentiophenone (some trade or other names: 4-MEAP);

4'-methyl-alpha-pyrrolidinohexiophenone (some trade or other names: MPHP);

Mephedrone (some trade or other names: Methylmethcathinone, 4-Methylmethcathinone, 4-MMC, 4-Methylephedrone);

Methamphetamine;

Methcathinone (some trade or other names: N-Methylcathinone, cat);

Methodrone (some trade or other names: Methoxymethcathinone, 4-Methoxymethcathinone, bk-PMMA, methoxyphedrine);

4-methyl-alpha-pyrrolidinopropiophenone (some trade or other names: 1-(4-methylphenyl)-2-(pyrrolidin-1-yl)-propan-1-one, 4-MePPP);

(±)cis-4-methylaminorex ((+)cis-4,5-dihydro-4-methyl-5-phenyl-2-oxazolamine);

Methylenedioxypyrovalerone (some trade or other names: 3,4-Methylenedioxypyrovalerone, MDPV);

Methylethcathinone (some trade or other names: 2-(ethylamino)-1-(4-methylphenyl)propan-1-one, 4-MEC, 4-methyl-N-ethylcathinone);

Methylone (some trade or other names: Methylenedioxy-N-methylcathinone, Methylenedioxymethcathinone, 3,4-Methylenedioxy-N-methylcathinone, bk-MDMA);

N,N-dimethylamphetamine (commonly referred to as N,N-alpha-trimethylbenzeneethanamine; N,N-alpha-trimethylphenethylamine);

N-ethylamphetamine;

Naphyrone (some trade or other names: 1-(naphthalen-2-yl)-2(pyrrolidin-1-yl)pentan-1-one, naphthylpyrovalerone, naphpyrovalerone, NRG-1, O-2482); or

- Pentedrone (some trade or other names: 2-(methylamino)-1-phenylpentan-1-one, α -methylaminovalerophenone)
- Pentylone (some other trade names: 1-(1,3-benzodioxol-5-yl)-2-(methylamino)pentan-1-one; beta-keto-methylbenzodioxolylpentanamine; bk-MBDP; bk-methyl-K)
- 8. Unless specifically listed in another schedule, coca leaves, cocaine base or free base, or a salt, compound, derivative, isomer or preparation thereof which is chemically equivalent or identical to such substances, and any quantity of material, compound, mixture or preparation which contains coca leaves, cocaine base or cocaine free base or its isomers or any of the salts of cocaine, except decocainized coca leaves or extractions which do not contain cocaine or ecgonine.
- 9. Unless specifically listed in another schedule Tetrahydrocannabinols (natural or synthetic equivalents of the substances contained in the plant, or in the resinous extractives of Cannabis, sp. or synthetic substances, derivatives and their isomers with similar chemical structure and pharmacological activity such as the following:
 - Delta 9 cis or trans tetrahydrocannabinol, and their optical isomers, also known as; Delta 1 cis or trans tetrahydrocannabinol, and their optical isomers,
 - Delta 8 cis or trans tetrahydrocannabinol, and their optical isomers, also known as; Delta 6 cis or trans tetrahydrocannabinol, and their optical isomers,
 - Delta 3, 4 cis or trans tetrahydrocannabinol, and its optical isomers;
 - Tetrahydrocannabinols contained in the genus Cannabis or in the resinous extractives of the genus Cannabis;
 - Synthetic equivalents of tetrahydrocannabinol substances or synthetic substances, derivatives and their isomers with a similar chemical structure; and

Since nomenclature of these substances is not internationally standardized, compounds of these structures, regardless of numerical designation of atomic positions covered).

10. Unless specifically listed in another schedule, any material, compound, mixture or preparation which contains any quantity of CBD (natural or synthetic equivalents of the substances contained in the plant or the resinous extractives of Cannabis sp. or synthetic substances. Derivatives and their isomers with similar chemical structure and pharmacological activity). Any CBD drug product that has been approved by the Food and Drug Administration and contains not more than 0.1 percent residual THC by weight is not a controlled substance.

Section 2. NAC 453.550 is hereby amended to read as follows:

NAC 453.550 Schedule V. (NRS 453.146, 639.070)

- 1. Schedule V consists of the drugs and other substances listed in this section, by whatever official, common, usual, chemical or trade name designated.
- 2. Any compound, mixture or preparation containing any of the following narcotic drugs or their salts calculated as the free anhydrous base alkaloid, containing one or more nonnarcotic active medicinal ingredients in sufficient proportion to confer upon the compound, mixture or preparation valuable medicinal qualities other than those possessed by the narcotic drug alone, in quantities:
 - (a) Not more than 200 milligrams of codeine per 100 milliliters or per 100 grams;
 - (b) Not more than 100 milligrams of dihydrocodeine per 100 milliliters or per 100 grams;
 - (c) Not more than 100 milligrams of ethylmorphine per 100 milliliters or per 100 grams;
- (d) Not more than 2.5 milligrams of diphenoxylate and not less than 25 micrograms of atropine sulfate per dosage unit;

- (e) Not more than 100 milligrams of opium per 100 milliliters or per 100 grams; or
- (f) Not more than 0.5 milligram of difenoxin and not less than 25 micrograms of atropine sulfate per dosage unit.
- 3. Unless specifically excepted or excluded or unless listed in another schedule, any material, compound, mixture or preparation which contains any quantity of pyrovalerone having a stimulant effect on the central nervous system, including their salts, isomers and salts of isomers.
- 4. Unless specifically excepted or excluded or unless listed in another schedule, any material, compound, mixture or preparation which contains any quantity of pregabalin having a depressant effect on the central nervous system, including their salts, isomers and salts of isomers.
 - 5. Lacosamide.
- 6. A drug product which:
 - (a) Has been approved by the United States Food and Drug Administration;
- (b) Contains CBD derived from any plant in the genus <u>Cannabis</u> or the resinous extractives thereof; and
- (c) Contains not more than 0.1 percent residual THC by weight.

TITLE: <u>Agenda Item 7</u> Discussion and possible action regarding amending the contract with Strategies 360 to extend the term and other potential amendments – For possible action.
RECOMMENDED MOTION: No recommendation.
PRESENTED BY: Margaret Colucci, DC
MEETING DATE: January 14, 2021
TIME REQUIRED: 15 minutes
BACKGROUND INFORMATION: The existing contract with Strategies 360 expires June 30, 2021.
REVIEWED BY: X President X Secretary X Executive Director
ACTION:ApprovedApproved w/ModificationsDenied Continued

AGENDA ACTION SHEET

TITLE: <u>Agenda Item 8</u> Discussion and potential action regarding the application for licensure of Carl Damailig, DC - For possible action. (Note: The Board may go into closed session pursuant to NRS 241 to consider the character alleged misconduct, or professional competence of Dr. Dimailig)

RECOMMENDED M	MOTION: No recommen	dation.				
PRESENTED BY:	Margaret Colucci, DC					
MEETING DATE:	January 14, 2021					
TIME REQUIRED: 20 minutes						
BACKGROUND IN	BACKGROUND INFORMATION: Please see the attached documentation.					
REVIEWED BY:	_X President _X	Secretary X	_Executive Di	rector		
ACTION: Appr	roved Approved w/	Modifications	Denied	Continued		

Agenda Item 8

CARL LAWRENCE DIMAILIG, DC

Doctor of Chiropractic Degree June 2008 Palmer College of Chiropractic

Examination

Dr. Dimailig has passed the National Board of Chiropractic Examiners Examination Parts I-IV and Physiotherapy in May 2008.

Reasons for Board Appearance:

- 1. Dr. Dimailig has not actively practiced chiropractic since 2017.
- 2. Dr. Dimailig's license may possibly need to be restricted, per his explanation as to why he ceased practice, and due to his current capabilities.
 - Please see Dr. Dimailig's explanation regarding why he ceased practice, his current capabilities, and what he has been doing to keep his knowledge current.

State Licensure

Dr. Dimailig holds an Expired license in California with no derogatory information indicated.

The National Practitioner Data Bank and Federation of Chiropractic Licensing Boards do not reflect any derogatory information.

Chiropractic Physicians' Board of Nevada January 2021 Application



TION FOR SENSE AS A DOCTOR OF CHIROPRACTIC 1. THE STATE OF NEVADA

CHIROPRACTIC PHYSICIANS' BOARD OF NEVADA

4600 KIETZKE LANE, SUITE M-245 RENO, NV 8902 Website: Chirobd.nv.gov CHIROPRACTIC PHYSICIANS
BOARD OF NEWADA

SEP 1 0 2020

TO ANSWER ALL QUESTIONS COMPLETELY AND TRUTHFULLY WILL RESULTIND
OF THIS APPLICATION. THE FEES ARE NOT REFUNDABLE.
NEVADA 89502

PRINT OR TYPE: CARL LAWRENCE DIMAILIG SEX: X M **FULL NAME** (FIRST) (MIDDLE) (LAST) ALIASES HOME ADDRESS 3. _ STATE NV __{ZIP} 89149 LAS VEGAS MAILING ADDRESS CITY LAS VEGAS STATE NV _{ZIP} 89149 WORK EMAIL SOCIAL SECURITY NO. TELEPHONE NO.__ PLACE OF BIRTH SAN FRANCISCO, CA 6. DATE OF BIRTH_ ARE YOU A UNITED STATES CITIZEN? YES NO IF YOU ANSWERED NO ARE YOU: (PLEASE CHECK ONE OF THE FOLLOWING.) A QUALIFIED ALIEN (AS DEFINED IN 8 U.S.C.A. § 1641). A NONIMMIGRANT UNDER THE IMMIGRATION AND NATIONALITY ACT (8 U.S.C.A. § 1101 et seq). AN ALIEN WHO IS PAROLED INTO THE UNITED STATES UNDER 8 U.S.C.A. § 1182(d) (5) FOR LESS THAN ONE YEAR. A FOREIGN NATIONAL NOT PHYSICALLY PRESENT IN THE UNITED STATES. OTHER - PLEASE PROVIDE DETAILED EXPLANATION. RESIDENT OF THE STATE OF NEVADA? Y IF YES, HOW LONG? 2 YRS NO V IF YES, PROVIDE YOUR LICENSE NUMBER DO YOU HAVE A NEVADA BUSINESS LICENSE? YES DATES OF SERVICE: FROM JUNE 1996 TO DEC 2001 BRANCH 10. HAVE YOU EVER SERVED IN THE MILITARY? YESXNO L (ES) OF SERVICE USMC 11. HAVE YOU EVER SERVED ON ACTIVE DUTY IN THE ARMED FORCES OF THE UNITED STATES AND SEPARATED FROM SUCH SERVICE UNDER CONDITIONS OTHER THAN DISHONORABLE? 12. HAVE YOU EVER BEEN ASSIGNED TO DUTY FOR A MINIMUM OF 6 CONTINUOUS YEARS IN THE NATIONAL GUARD OR A RESERVE COMPONENT OF THE ARMED FO CE OF THE UNITED STATES AND SEPARATED FROM SUCH SERVICE UNDER CONDITIONS YES NO HONORABLE?

13.	HAVE YOU EVER SERVED THE COMMISSIONED CORPS OF THE UNITED STATES PUBLIC HEALTH SERVICE OR THE COMMISSIONE CORPS OF THE NATIONAL OCEANIC AND ATMOSPHERIC ADMINISTRATION OF THE UNITED STATES IN THE CAPACITY OF A COMMISSIONED OFFICER WHILE ON ACTIVE DUTY IN DEFENSE OF THE UNITED STATES AND SEPARATED FROM SUCH SERVICE
14.	UNDER CONDITIONS OTHER THAN DISHONORABLE?YESNO RESIDENCE ADDRESSES FOR PAST FIVE (5) YEARS:2018-PRESENT, 9064 HANGING TAPESTRY CT LAS VEGAS NV 89149
20	15-2018, 81 PARKHAVEN DR VALLEJO CA 94591
15.	NAMES AND ADDRESSES OF ALL EMPLOYERS FOR PAST FIVE (5) YEARS: SELF EMPLOYED
16.	Please read questions #16 through #18 carefully. If you have any questions please contact the Board. HAVE YOU EVER HAD DISCIPLINARY ACTION BROUGHT AGAINST YOU BY A STATE BOARD OR ANY OTHER GOVERNMENTAL AGENCY, OR IS THERE ANY SUCH ACTION NOW PENDING? VES NO IF YES, GIVE DETAILS AND FINAL DISPOSITION:
_	
17.	HAVE YOU EVER BEEN ARRESTED FOR OR CHARGED WITH ANY CRIME OTHER THAN A TRAFFIC VIOLATION (INCLUDE ANY DUI'S NOTE: EVEN IF YOU HAVE HAD RECORDS SEALED AND YOU HAVE BEEN TOLD THAT YOUR FILE HAS BEEN CLEARED, YOU MU REPORT THIS INFORMATION, INCLUDING JUVENILE RECORDS. YES NO IF YES, GIVE DETAILS AND FINAL DISPOSITION.
18.	HAVE YOU EVER BEEN CONVICTED OF A CRIME OTHER THAN A TRAFFIC VIOLATION (INCLUDE ANY DUI'S)? NOTE: EVEN IF YOU HAVE HAD RECORDS SEALED AND YOU HAVE BEEN TOLD THAT YOUR FILE HAS BEEN CLEARED, YOU MUST REPORT THIS INFORMATION, INCLUDING JUVENILE RECORDS. YES NO IF YES, GIVE DETAILS AND FINAL DISPOSITION:
_	
19.	HAVE YOU EVER DEFAULTED ON A HEAL (HEALTH EDUCATION ASSISTANCE LOAN)? YES NO IF YES, GIVE DETAIL AND CURRENT STATUS:
_	
-	

20.	REGARDING CHILD SUPPORT, MARK THE APPROPRIATE RESPONSE (FAILURE TO MARK ONE OF THE THREE WILL RESULT IN DENIAL OF THE APPLICATION):						
	I AM NOT SUBJECT TO A COURT ORDER FOR THE SUPPORT OF A CHILD OR CHILDREN.						
	I <u>AM</u> SUBJECT TO A COURT ORDER FOR THE SUPPORT OF ONE OR MORE CHILDREN AND <u>AM</u> IN COMPLIANCE WITH THE ORDER OR I AM IN COMPLIANCE WITH A PLAN APPROVED BY THE DISTRICT ATTORNEY OR OTHER PUBLIC AGENCY ENFORCING THE ORDER FOR THE REPAYMENT OF THE AMOUNT OWED PURSUANT TO THE ORDER.						
	I <u>AM</u> SUBJECT TO A COURT ORDER FOR THE SUPPORT OF ONE OR MORE CHILDREN AND <u>AM NOT</u> IN COMPLIANCE WITH THE ORDER OR A PLAN APPROVED BY THE DISTRICT ATTORNEY OR OTHER PUBLIC AGENCY ENFORCING THE ORDER FOR THE REPAYMENT OF THE AMOUNT OWED PURSUANT TO THE ORDER.						
21.	REGARDING CHILD ABUSE, THE FOLLOWING MUST BE READ AND INITIALED:						
	I HAVE BEEN INFORMED THAT I AM REQUIRED BY LAW TO REPORT THE ABUSE OR NEGLECT OF A CHILD TO AN AGENCY THAT PROVIDES CHILD WELFARE SERVICES OR TO A LAW ENFORCEMENT AGENCY NO LATER THAN 24 HOURS AFTER I KNEW OR HAD REASONABLE CAUSE TO BELIEVE THE CHILD HAD BEEN ABUSED OR NEGLECTED.						
	Please initial here, thereby acknowledging that you have read and understood the above information: Date: 10/20/2020						
22.	HAVE YOU EVER BEEN DRUG OR ALCOHOL DEPENDENT AND/OR ENROLLED IN A DRUG OR ALCOHOL REHABILITATION PROGRAM? YES NO IF YES, GIVE DETAILS:						
23.	ARE YOU CURRENTLY WORKING FOR A NEVADA LICENSED CHIROPRACTOR? YES NO IF YES, GIVE LICENSEE'S NAME						
	AND ADDRESS:						
	DATE EMPLOYED: DUTIES PERFORMED:						
24.	LIST ALL SCHOOLS ATTENDED (HIGH SCHOOL THROUGH CHIROPRACTIC COLLEGE):						
	NAME OF SCHOOL DATES ATTENDED DATE GRADUATED DEGREE PALMER COLLEGE OF CHIROPRACTIC APR '05-JUN '08 JUN 2008 DC						
	SAN JOSE STATE UNIVERSITY JAN '02-JUN '04						
	DEVRY UNIVERSITY JUL '03-MAR '05 MAR 2005 BS						
25	NUMBER OF CHIROPRACTIC COLLEGE HOURS 5076 DATE OF D.C. DEGREE JUNE 2008						
26	. HAVE YOU PASSED NATIONAL BOARD: PART I PART II PART III PART III PART IV PET SPEC						
27	. IF YOU ANSWERED "NO" TO PART IV AND SPEC, YOU MUST GIVE DATE YOU ARE SCHEDULED FOR ONE OF THE FOLLOWING						
	EXAMS: PART IV: or SPEC:						
28	. LIST ANY STATES IN WHICH YOU HAVE APPLIED FOR (WHETHER ISSUED OR NOT) AND IN WHICH YOU HAVE BEEN GRANTED CHIROPRACTIC LICENSURE:						
	STATE STATUS DATE OF ISSUANCE						
	CA EXPIRED OCTOBER 14, 2008						

DRY NEEDLING CERTIFICATION - NOT REQUIRED FOR LICENSURE

29. HAVE YOU BEEN CERTIFIED TO PERFORM DECONFIRM 50 HOURS OF CONTINUING EDUCA		NO 🗸	IF YES, PROVIDE T	HE CERTIFICATE(S)	ТО
Please read the Affidavit carefully.					
AFFIDAVIT:					
THE UNDERSIGNED, BEING DULY SWORN UNI HEREIN ARE TRUE, COMPLETE, AND CORRISUPPRESSED ANY INFORMATION WHICH MIGRELEVANT TO HIS/HER CURRENT FITNESS TO ETHICAL STANDARDS AND CONDUCT OF THE INFORMATION IN THIS APPLICATION, INCLUDI REQUIREMENTS AND BELIEVES HIM/HERSELF AND UNDERSTANDS THIS AFFIDAVIT. (DATE)	ECT TO THE BEST OF HIS BHT AFFECT THIS APPLICA' PRACTICE; THAT HE/SHE IS PROFESSION; THAT HE/SHE NG CHANGES OF ADDRESS	S/HER KNOWLE TION; THAT HE G OF GOOD MOR E WILL NOTIFY T S AND THAT HE TO PRACTICE O	EDGE AND BELIEF /SHE HAS NOT ON RAL CHARACTER AI THE CPBN OF ANY I //SHE HAS OTHER	F; THAT HE/SHE HA MITTED ANY INFOR ND WILL CONFORM AND ALL CHANGES WISE MET ALL STAT D THAT HE/SHE HA	AS NOT MATION TO THE TO THE
STATE OF Nevada COUNTY OF	Clark				
SIGNED AND SWORN TO BEFORE ME ON T	THIS 8 DAY OF.	Septem	ber,	20.20	
(NOTARY PUBLIC			DALTON Notary Public-S Appointment N My Appointment Ex	tate of Nevada X No. 19-1549-1 pires Feb. 3, 2023	

Dr. Dimailig's explanation regarding ceasing the practice of Chiropractic

October 20, 2020

Chiropractic Physician's Board of Nevada 4600 Kietzke Lane, M-245 Reno NV 89502-5000

To whom it may concern,

After having been in full-time practice for nearly nine years, I abruptly had to quit my practice in 2017. There were some injuries I received back when I was active duty in the Marine Corps that I thought were resolved before beginning my chiropractic education. Unfortunately not, and I became rated with significant service-connected disabilities, the most impactful being a frequently recurring neuropathy and partial loss of function in my dominant hand.

To generate income for myself, I have become a business finance consultant. This was a natural fit because of my clinic and office experience while having less strenuous physical requirements. Even though I am not physically able to adjust patients, I have been staying current with health topics such as nutrition and injury prevention. Now that I have adapted my career to accommodate my physical restrictions, I feel competent that, if allowed to become licensed in the State of Nevada, I would be fully capable of becoming a health care provider with a limited scope of nutrition and ergonomic consulting.

Thank you,

Carl Dimailig, DC

AGENDA ACTION SHEET

TITLE: Agenda Item 9 Discussion and possible action regarding the handling of requests to

consider proof of for possible action	ormal chiropractor's assistant ti	training pursuant to NAC 634.344 (4) (b) -	-
RECOMMENDED N	MOTION:		
PRESENTED BY:	Margaret Colucci, DC		
MEETING DATE:	January 14, 2021		
TIME REQUIRED:	15 minutes		
		15, 2020 meeting it was recommended that anslate credits earned to on-the-job-training	
REVIEWED BY:	X President X Secret	etary X Executive Director	
ACTION: App	roved Approved w/Modifica	ations Denied Continued	

AGENDA ACTION SHEET

TITLE: <u>Agenda Item 10</u> Consideration of including the supervising chiropractic physicians' signature on the Chiropractor's Assistant application – For possible action.

RECOMMENDED MOTION: Recommend leaving the chiropractor's assistant application as is, since NAC 634.355 (3) requires that the chiropractic physician sign a separate form, acknowledging that the CA completed the requisite 6 or 12 hours of on-the-job training prior to sitting for the examinations.

PRESENTED BY: Margaret Colucci, DC

MEETING DATE: October 15, 2020

TIME REQUIRED: 15 minutes

BACKGROUND INFORMATION: At the October 15, 2020 Board meeting the Board discussed a request, requiring the supervising DC to sign the CA application acknowledging that they are responsible for the CA's on-the-job training. However, NAC 634.355(3) requires the DC to acknowledge a CA's training.

NAC 634.355 Certification: Additional requirements; waiver of requirements. (NRS 634.030, 634.123)

3. Evidence of an applicant's completion of approved training pursuant to subparagraph (2) of paragraph (a) of subsection 2 must consist of a certification by each licensee who supervised the work and training of the applicant.

REVIEWED	BY: <u>X</u>	President X	_ Secretary _	_ <u>X</u>	_Executive	e Director
ACTION:	Approved	Approved w/N	Modifications	S	Denied _	Continued

AGENDA ACTION SHEET

TITLE: <u>Agenda Item 11</u> Consideration of potential additions, deletions, and/or amendments to NRS 634 and NAC 634– For possible action.

A. Discipline for failing to submit Self-Inspection by March 31.

RECOMMENDED M	MOTION:
PRESENTED BY:	Margaret Coluuci DC
MEETING DATE:	January 14, 2021
TIME REQUIRED:	10 minutes
	FORMATION: At the October 15, 2020 Board meeting there were several mending a fine of \$150 to \$300 be administered, however did not pass.
REVIEWED BY:	X President X Secretary X Executive Director
ACTION:App	rovedApproved w/ModificationsDenied Continued

TITLE:				n policy and pro the Board's co		
RECOM	MENDED M	MOTION: N	No recommend	ation.		
PRESEN	NTED BY:	James Ov	erland, Sr., DC	C/Morgan Rovet	ti, DC	
MEETIN	NG DATE:	January 1	4, 2021			
TIME R	EQUIRED:	10 minute	s			
BACKG	ROUND IN	FORMATIC	ON:			
REVIEV	VED BY:	_ <u>X</u> P1	resident <u>X</u>	_Secretary <u>X</u> _	Executive Dis	rector
ACTION	N:App	roved	_Approved w/M	Iodifications	Denied	Continued

TITLE: <u>Agenda Item 13</u> Discussion and possible action regarding chiropractic physicians including Qualified Medical Examiner (QME) on their Nevada letterhead – For possible action.
RECOMMENDED MOTION: Determine whether it is appropriate for a DC who is licensed in Nevada and California to advertise QME on their Nevada letterhead.
PRESENTED BY: Margaret Colucci, DC
MEETING DATE: January 14, 2021
TIME REQUIRED: 15 minutes
BACKGROUND INFORMATION: Please see the attached letter which was forwarded to the Board by an active chiropractic physician inquiring whether it is appropriate for a licensee to advertise QME, which is a California designation, on his Nevada letterhead.
REVIEWED BY: <u>X</u> President <u>X</u> Secretary <u>X</u> Executive Director
ACTION:ApprovedApproved w/ModificationsDenied Continued

To:7771367

Page:3/8

CHIROPEACTIC PHYSICIANS' BOARD OF NEVADA

OCT 20 2020

DC, DABCO, QME RENO, RECEIVED RENO, NEVADA 89502

PPDs, IMEs, Impairment Ratings and Reviews For Workers Compensation and Personal Injury

RENO CLINIC



October 12, 2020

LAS VEGAS CLINIC

Email: QMEs in Southern California

CARSON CITY CLINIC

AGENDA ACTION SHEET

TITLE: <u>Agenda Item 14</u> Discussion and potential action regarding chiropractic physicians whose licenses expired effective January 1 and potentially may be continuing to practice on expired licenses – For possible action

RECOMMENDED MOTION: Based on the response or lack of from the certified letter sent to the expired DC requiring them to cease and desist practicing, the Board may want to set the tone on how to handle DC's that we do not receive a response from.

- Attempt to make contact by telephone.
- If the DC has a valid practice address send an investigator by to confirm the DC is or is not practicing.
- If the DC is practicing with an expired license, identify disciplinary action.

PRESENTED BY:	Margaret Colucci, DC

MEETING DATE: January 14, 2021

TIME REQUIRED: 15 minutes

BACKGROUND INFORMATION: The attached cease and desist letter is sent via certified mail to all expired licensees as soon as possible following the 1st of January. This year the letters were sent on January 5, 2021.

REVIEWED I	3Y: <u>X</u>	_ President <u>X</u>	Secretary _	<u>X</u>	_Executive	Director
ACTION:	Approved	Approved w/	Modifications	S	Denied	Continued

STATE OF NEVADA

STEVE SISOLAK
Governor

Margaret Colucci, DC
President
Nicole Canada, DC
Vice President
James Overland Sr., DC
Secretary-Treasurer



Morgan Rovetti, DC
Member
Xavier Martinez, DC
Member
Tracy DiFillippo, ESQ
Consumer Member
John L. Bertoldo, ESQ
Consumer Member

CHIROPRACTIC PHYSICIANS' BOARD OF NEVADA

4600 Kietzke Lane, Suite M245 Reno, Nevada 89502-5000 Telephone (775) 688-1921

Website: http://chirobd.nv.gov Fax (775) 688-1920 Email: chirobd@chirobd.nv.gov

January 4, 2021

, DC

Re: Expiration of Chiropractic License

Dear Dr.,

The Boards' records indicate that you did not apply for renewal of your Nevada chiropractic license for the 2021/2022 renewal period.

Your license automatically expired effective January 1, 2021, for not submitting the complete renewal. Pursuant to NRS 634.130, if a licensee fails to pay his or her renewal fee by January 1 of an odd-numbered year, fails to submit proof of the required continuing education, or fails to submit all information required to complete the renewal, the license automatically expires and may be reinstated only upon the payment of the required fee for reinstatement in addition to the renewal fee.

You are hereby ordered to immediately **CEASE AND DESIST** practicing chiropractic in the State of Nevada until you have completed all of the requirements for renewal of your license.

To reinstate your license, please access the Boards' website at chirobd.nv.gov, select Application Info and download the Application for Activation of License. Submit the application, proof of 36 hours of continuing education, a completed fingerprint card and the fee as follows: The reinstatement fee for active status is \$500.00, \$700.00 renewal fee, \$25.00 paper renewal fee, and \$40.25 for the background check. In addition, you must request verification of any licensure that you hold in another state or states (to include Active, Inactive, or Expired licensure status). We cannot reinstate your license until your complete renewal is received, and all other requirements have been met.

If you find that we are in error, please send us verifiable evidence that your payment and documentation of your attendance of 36 hours of approved continuing education was submitted to the Board by 11:59 p.m. on December 31, 2020. Please contact this office if you have any questions.

Sincerely,

Julie Strandberg Executive Director

AGENDA ACTION SHEET

TITLE: <u>Agenda Item 15</u> Status report regarding anonymous profiles of possible disciplinary actions. Board action will be limited to either dismissing the matter if the Board determines there is no violation, it has no jurisdiction over the subject, or providing direction to pursue the matter further – For possible action.

direction t	o pursue the matter for	urther – For possible	action.	
RECOMMENDED	MOTION: No recom r	nendation		
PRESENTED BY:	Margaret Colucci, I	DC		
MEETING DATE:	January 14, 2021			
TIME REQUIRED:	40 minutes			
BACKGROUND IN	FORMATION:			
A. B. C. D. E. F. G. H. I. J. K. L. M. N. O.	Complaint 17-28S Complaint 18-13S Complaint 18-15S Complaint 18-17S Complaint 19-03S Complaint 19-12S Complaint 19-16S Complaint 20-01N Complaint 20-03N Complaint 20-04N Complaint 20-10S Complaint 20-12S Complaint 20-13S Complaint 20-14S Complaint 20-15N	(Colucci) (Rovetti) (Canada) (Canada) (Canada) (Rovetti) (Canada) (Rovetti) (Rovetti) (Colucci) (Martinez) (Canada) (Colucci) (Colucci) (Canada)		
REVIEWED BY:	X President	X Secretary _X_	Executive D	irector
ACTION: Ap	proved Approved	d w/Modifications	Denied	Continued

Agenda Item 15

TITLE: <u>Agenda Item 15A</u> Status report regarding anonymous profiles of possible disciplinary actions. Board action will be limited to either dismissing the matter if the Board determines there is no violation, it has no jurisdiction over the subject, or providing direction to pursue the matter further – For possible action:
A. Complaint 17-28S (Dr. Colucci)
RECOMMENDED MOTION: A citation has been issued.
PREPARED BY: Maggie Colucci, DC
MEETING DATE: January 14, 2021
TIME REQUIRED: 3 minutes
BACKGROUND INFORMATION: The Board was notified by the National Practitioners Data Bank that a DC settled a malpractice claim, which is to be reported to the Board by the DC within 15 days pursuant to NAC 634.425. To date the DC has not notified the Board of this action. The DC retained an attorney and the Settlement Agreement & Order will be delivered to the attorney.
REVIEWED BY: X President X Secretary X Executive Director ACTION:ApprovedApproved w/ModificationsDeniedContinued

AGENDA ACTION SHEET

TITLE:	Agenda Item 15B Status report regarding anonymous profiles of possible disciplinary
	actions. Board action will be limited to either dismissing the matter if the Board
	determines there is no violation, it has no jurisdiction over the subject, or providing
	direction to pursue the matter further – For possible action:
	•

B. Complaint 18-13S (Dr. Rovetti)
RECOMMENDED MOTION:

PREPARED BY: Morgan Rovetti, DC

MEETING DATE: January 14, 2021

TIME REQUIRED: 3 minutes

BACKGROUND INFORMATION: This complaint originated with Farmers Insurance through the National Insurance Crime Bureau with respect to a Physical Therapy group. The concern are the charges and the use of billing codes and what appears to possibly be a chiropractic adjustment.

REVIEWED I	BY:	<u>X</u>	_ President _	<u>X</u>	Secretary _	<u>X</u>	Executive Director
ACTION:	Appro	oved	Approved v	w/Mod	ifications	Denied	Continued

TITLE: <u>Agenda Item 15C</u> Status report regarding anonymous profiles of possible disciplinary actions. Board action will be limited to either dismissing the matter if the Board determines there is no violation, it has no jurisdiction over the subject, or providing direction to pursue the matter further – For possible action:
C. Complaint 18-15S (Dr. Canada)
RECOMMENDED MOTION:
PREPARED BY: Nicole Canada, DC
MEETING DATE: January 14, 2021
TIME REQUIRED: 3 minutes
BACKGROUND INFORMATION: The complainant alleged that the DC is allowing staff to perform unsupervised CA duties in the office.
REVIEWED BY: X President X Secretary X Executive Director
ACTION:ApprovedApproved w/ModificationsDenied Continued

AGENDA ACTION SHEET

a	ections. B letermines	oard action we there is no vi	report regarding anonymous profiles of possible disciplinary vill be limited to either dismissing the matter if the Board iolation, it has no jurisdiction over the subject, or providing atter further – For possible action:
I	O. Comp	laint 18-17S	(Dr. Canada)
RECOMM	MENDED N	MOTION:	
PREPARE	ED BY:	Nicole Canad	la, DC
MEETING	G DATE:	January 14, 2	2021
TIME RE	QUIRED:	3 minutes	
		FORMATION: chiropractic.	The complainant alleged that the chiropractor is acting

REVIEWED BY: \underline{X} President \underline{X} Secretary \underline{X} Executive Director

ACTION: ____Approved ____Approved w/Modifications ____Denied ____ Continued

AGENDA ACTION SHEET

TITLE:	action determ	is. Bos mines t	ard action here is no	n will be li violation,	imited t	o either dis	missing on over	the matter if the	Boar
	E.	Compla	int 19-03	S (Dr. Ca	ınada)				
RECOM	IMENI	DED MO	OTION:						
PREPAI	RED B	Y: 1	Nicole Ca	nada, DC					
MEETIN	NG DA	TE:	October 1	5, 2020					
TIME R	EQUIF	RED:	3 minutes	}					
				ON: The coes in the off	-	ant alleged	that the	DC is allowing s	taff to
REVIEV	WED B	Y: _	<u>X</u>	President _	<u>X</u>	_Secretary _	<u>X</u>	Executive Director	r

ACTION: ____Approved ____Approved w/Modifications ____Denied ____ Continued

AGENDA ACTION SHEET

TITLE: <u>Agenda Item 15F</u> Status report regarding anonymous profiles of possible disciplinary actions. Board action will be limited to either dismissing the matter if the Board determines there is no violation, it has no jurisdiction over the subject, or providing direction to pursue the matter further – For possible action:

F. Complaint 19-12S (Dr. Rovetti)

RECOMMENDED MOTION:

PREPARED BY: Morgan Rovetti, DC

MEETING DATE: January 14, 2021

TIME REQUIRED: 3 minutes

BACKGROUND INFORMATION: The complainant alleged unprofessional conduct.

REVIEWED BY: X President X Secretary X Executive Director

ACTION: Approved Approved w/Modifications Denied Continued

TITLE:	actions. Bo	oard action there is no	will be li violation,	mited to	either disi	nissing n over	es of possible disciplinary the matter if the Board the subject, or providing
	G. Compl	laint 19-16 S	S (Dr. Ca	nada)			
RECOM	MENDED M	IOTION: Is	ssue a citati	on.			
PREPAR	RED BY:	Nicole Car	nada, DC				
MEETIN	IG DATE:	January 1	4, 2021				
TIME R	EQUIRED:	3 minutes					
Howeve		ing the offi	ce, staff did	l not ha	ve their wall	certific	unprofessional conduct. ates properly displayed. the DC.
REVIEV	VED BY:	<u>X</u>	President _	<u>X</u>	Secretary	X	Executive Director
ACTION	N:Appr	oved	Approved v	v/Modifi	cations	_Denied	Continued

AGENDA ACTION SHEET

TITLE: <u>Agenda Item 15H</u> Status report regarding anonymous profiles of possible disciplinary actions. Board action will be limited to either dismissing the matter if the Board determines there is no violation, it has no jurisdiction over the subject, or providing direction to pursue the matter further – For possible action:

Н. Сотр	laint 20-01N (Dr. Rovetti)
RECOMMENDED N	MOTION:
PREPARED BY:	Morgan Rovetti, DC
MEETING DATE:	January 14, 2021
TIME REQUIRED:	3 minutes
BACKGROUND IN	FORMATION: The complainant alleged unprofessional conduct.
REVIEWED BY:	X President X Secretary X Executive Director
ACTION: App	roved Approved w/Modifications Denied Continued

AGENDA ACTION SHEET

TITLE: <u>Agenda Item 151</u> Status report regarding anonymous profiles of possible disciplinary actions. Board action will be limited to either dismissing the matter if the Board determines there is no violation, it has no jurisdiction over the subject, or providing direction to pursue the matter further – For possible action:

I	1-:4 20, 020	(Day Dagas 442)			
I. Comp	1aint 20-038	(Dr. Rovetti)			
RECOMMENDED M	MOTION:				
PREPARED BY:	Morgan Rov	etti, DC			
MEETING DATE:	January 14,	2021			
TIME REQUIRED:	3 minutes				
BACKGROUND INI records to him.	FORMATION	: Complainant	alleged that t	he DC w	vill not release his wife'
REVIEWED BY:	<u>X</u> Pr	esident <u>X</u>	Secretary	<u>X</u>	Executive Director
ACTION: Appr	roved A1	oproved w/Modi	fications	Denied	Continued

AGENDA ACTION SHEET

actions. determin	<u>Item 15J</u> Status report regarding anonymous profiles of possible disciplinary Board action will be limited to either dismissing the matter if the Board nes there is no violation, it has no jurisdiction over the subject, or providing a to pursue the matter further – For possible action:
J. Co	mplaint 20-04S (Dr. Colucci)
RECOMMENDE	O MOTION: Recommend dismissal.
PREPARED BY:	Maggie Colucci, DC
MEETING DATE	: January 14, 2021
TIME REQUIREI	D: 3 minutes
BACKGROUND unlicensed practi	INFORMATION: Anonymous complainant alleged that a DC is operating an ce.
REVIEWED BY:	X President X Secretary X Executive Director

ACTION: ____Approved ____Approved w/Modifications ____Denied ____ Continued

AGENDA ACTION SHEET

TITLE: <u>Agenda Item 15K</u> Status report regarding anonymous profiles of possible disciplinary actions. Board action will be limited to either dismissing the matter if the Board determines there is no violation, it has no jurisdiction over the subject, or providing direction to pursue the matter further – For possible action:

	•
K. Comp	plaint 20-10S (Dr. Martinez)
RECOMMENDED N	MOTION:
PREPARED BY:	Xavier Martinez, DC
MEETING DATE:	October 15, 2020
TIME REQUIRED:	3 minutes
BACKGROUND IN	FORMATION: The complainant alleged unprofessional conduct.
REVIEWED BY:	X President X Secretary X Executive Director
ACTION:App	provedApproved w/ModificationsDenied Continued

AGENDA ACTION SHEET

TITLE: <u>Agenda Item 15L</u> Status report regarding anonymous profiles of possible disciplinary actions. Board action will be limited to either dismissing the matter if the Board determines there is no violation, it has no jurisdiction over the subject, or providing direction to pursue the matter further – For possible action:

голого го р	
L. Complain	nt 20-12S (Dr. Canada)
RECOMMENDED MO	TION:
PREPARED BY: N	icole Canada, DC
MEETING DATE: Ja	anuary 14, 2021
TIME REQUIRED: 3	minutes
BACKGROUND INFO	RMATION: Complainant alleged unprofessional conduct.
REVIEWED BY:	X President X Secretary X Executive Director
ACTION:Approv	redApproved w/ModificationsDenied Continued

Agenda Item 15L

M. Complaint 20-13S (Dr. Colucci)
RECOMMENDED MOTION:
PREPARED BY: Maggie Colucci, DC
MEETING DATE: January 14, 2021
TIME REQUIRED: 3 minutes
BACKGROUND INFORMATION: Complainant alleged that the chiropractor and staff are not following COVID-19 guidelines with respect to providing clean equipment.
REVIEWED BY: X President X Secretary X Executive Director ACTION: Approved Approved Modifications Denied Continued

AGENDA ACTION SHEET

TITLE:	actions. Bo	oard action v	will be lin iolation, i	nited to	either dis o jurisdicti	smissing on over t	s of possible disciplinary the matter if the Board the subject, or providing
	N. Comp	laint 20-14S	(Dr. Col	ucci)			
RECOM	MENDED M	IOTION: Rec	commend	dismiss	al.		
PREPAR	RED BY:	Maggie Colu	cci, DC				
MEETIN	NG DATE:	January 14,	2021				
TIME RI	EQUIRED:	3 minutes					
BACKG		FORMATION	: The DC	C report	ed Board o	discipline	on his Nevada inactive
REVIEW	VED BY:	<u>X</u> Pr	esident	<u>X</u>	Secretary _	<u>X</u>	Executive Director
ACTION	N:App1	rovedA	pproved w	/Modifi	cations	Denied	Continued

AGENDA ACTION SHEET

TITLE: Agenda Item 150 Status report regarding anonymous profiles of possible disciplinary actions. Board action will be limited to either dismissing the matter if the Board determines there is no violation, it has no jurisdiction over the subject, or providing direction to pursue the matter further – For possible action:						
O. Complaint 20-15N (Dr. Canada)						
RECOMMENDED MOTION:						
PREPARED BY: Nicole Canada, DC						
MEETING DATE: January 14, 2021						
TIME REQUIRED: 3 minutes						
BACKGROUND INFORMATION: The DC's website provided a procedure being done by the DC that is outside the scope of chiropractic.						
REVIEWED BY: X President X Secretary X Executive Director						

ACTION: ____Approved ____Approved w/Modifications ____Denied ____ Continued

AGENDA ACTION SHEET

TITLE: <u>Agenda Item 16</u> Board Counsel Report – For possible action.					
RECOMMENDED N	MOTION: No recommendation				
PRESENTED BY:	Louis Ling, Esq.				
MEETING DATE:	January 14, 2021				
TIME REQUIRED:	10 minutes				
BACKGROUND INI	FORMATION:				
REVIEWED BY:	<u>X</u> President <u>X</u> Secretary <u>X</u> Executive Director				
ACTION:App	rovedApproved w/ModificationsDenied Continued				

AGENDA ACTION SHEET

TITLE: <u>Agenda Item 17 FCLB/NBCE Matters – For possible action.</u>

- A. Selection of Board's choice for FCLB Voting Delegate
- A. Selection of Board's choice for FCLB Alternate Delegate
- B. Selection of Board's choice for NBCE Voting Delegate
- C. Selection of Board's choice for NBCE Alternate Delegate
- D. Attendance of Board Member(s) at the FCLB annual conference to be held in West Palm Beach, FL April 28 May 2, 2021
- E. Selection of Board Member to participate in the Spring National Board Part IV Exam May 21-23, 2021
- F. Selection of Board Member to participate in the National Board Part IV Test Committee meeting June 11-12, 2021
- **G.** Selection of Board Member to participate in the Fall National Board Part IV Exam November 12-14, 2021

RECOMMENDED N	MOTION:			
PRESENTED BY:	Margaret Colucci, DC			
MEETING DATE:	January 14, 2021			
TIME REQUIRED:	10 minutes			
BACKGROUND IN	FORMATION:			
REVIEWED BY:	_X President _X	SecretaryX	_Executive D	Director
ACTION:App	rovedApproved w/	Modifications	Denied	Continued

Susan Brown Director

Tiffany Greenameyer
Deputy Director

Warren Lowman Administrator

209 E. Musser Street, Suite 200 | Carson City, NV 89701-4298 Phone: (775) 684-0222 | www.budget.nv.gov | Fax: (775) 687-0260

ALL AGENCY MEMO 2020-15

June 25, 2020

To:

All Agency Directors

From:

Susan Brown, Director

Subject:

REVISED Travel Guidance in Response to 2019 Novel Coronavirus

(COVID-19)

As Nevada progresses through the phases of the Nevada United: Roadmap to Recovery plan, the following revised guidance on travel for state employees is being put in place as of the date of this memorandum.

Only essential travel is authorized at this time. Heads of Executive Branch Departments and Agencies are authorized to determine what travel meets the essential threshold. If agencies do not already have a policy requiring agency leadership to review and approve in-state travel, essential travel should be reviewed in the current circumstances. When determining whether in-state travel is essential, agency heads should consider factors such as:

- If the purpose of travel is to perform essential duties related to the protection of life and property; or
- If the purpose of travel is for an essential employee to perform his or her duties;
- If the travel is for systems or equipment inspections integral to security, safety, or proper functioning of the mission; and
- Whether the employee can reasonably perform his or her duties via phone or video conference in lieu of travel.

Although air travel is permitted, where possible, it is recommended that approved travel occurs by agency vehicle, rentals from Fleet Services, or state-contracted private car rental services such as Enterprise or Hertz. Finally, personal vehicles may be used and may be reimbursed at the higher mileage rate for the State's convenience.

At this time, the Governor's Office continues to recommend that, where possible, meetings are conducted via phone or video conference (where social distancing can be accomplished).

All out of state and international travel must receive written approval from the Director and Governor's Office.

Before traveling away from their local communities, employees should consider the following:

- Is COVID-19 spreading where you're going? You can get infected while traveling.
- Is COVID-19 spreading in your community? Even if you don't have symptoms, you can spread COVID-19 to others while traveling.
- Will you or those you are traveling with be within 6 feet of others during or after your trip? This increases your risk of getting infected and infecting others.
- Are you or other travelers at high risk of becoming hospitalized from COVID-19?
- Do you live with someone who is at high risk of becoming hospitalized from COVID-19?
- Does the city or county where you live or visit require you to stay home for 14 days after traveling?

Do not travel if you are sick, or if you have been around someone with COVID-19 in the past 14 days. Do not travel with someone who is sick.

The Centers for Disease Control's webpage has more information about travel.

AGENDA ACTION SHEET

TITLE:	Agenda	Item 1	18 Con	ımittee	Reports
--------	---------------	--------	--------	---------	---------

- A. Continuing Education Committee (Dr. Martinez) For possible action.
- B. Legislative Committee (Dr. Colucci) For possible action.
- C. Preceptorship Committee (Dr. Rovetti) For possible action.
- D. Test Committee (Dr. Canada) For possible action.

RECOMMENDED M	MOTION: No	recommendation	n.		
PREPARED BY:	Margaret Co	olucci, DC			
MEETING DATE:	January 14,	2021			
TIME REQUIRED:	15 minutes				
BACKGROUND IN	FORMATION	ſ:			
REVIEWED BY:	X Pr	residentX	_ Secretary _	<u>X</u>	_Executive Director
ACTION: Appr	roved A	pproved w/Modi	fications	Denied	1 Continued

AGENDA ACTION SHEET

TITLE:	Agenda	Item 19	Executive	Director	Reports:
--------	---------------	----------------	-----------	----------	-----------------

- Status of Pending Complaints No action. A.
- Status of Current Disciplinary Actions No action. B.
- C. **Legal/Investigatory Costs – No action.**
- Board Audit (Bertrand & Associates) For possible action. Contract with Bertrand & Associates For possible action.

E. Contr	act with	Bertrand & A	Associa	tes – For poss	ible act	ion.
RECOMMENDED N	MOTION:	No recommo	endatio	on.		
PREPARED BY:	Julie St	randberg, Ex	ecutive	Director		
MEETING DATE:	January	14, 2021				
TIME REQUIRED:	5 minu	tes				
BACKGROUND IN	FORMAT	TION:				
REVIEWED BY:	_X	President	_X	Secretary	<u>X</u>	_Executive Director
ACTION:App	roved	Approved	w/Mod	ifications	_Denie	d Continued

17-28S	9/12/2017	Colucci	Failure to report malpractice claim	Pending Settlement Agreement
18-13S	8/20/2018	Rovetti	Allegedly practicing outside the scope of a physical therapist	Under investigation
	, ,			-
18-15S	9/25/2018	Canada	Allegedly allowing staff to perform duties while absent from the office.	Under Investigation
18-17\$	11/2/2018	Canada	Allegedly acting outside the scope of chiropractic	Under investigation
19-03S	4/22/2242	Carrada	Allege die alleggies staff to grant gans de ties while also at from the affice	Under in continution
15-033	4/22/2019	Canada	Allegedly allowing staff to perform duties while absent from the office.	Under investigation
19-12S	9/18/2019	Rovetti	Alleged unprofessional conduct	Under investigation
				-
19-16S	11/18/2019	Canada	Alleged unprofessional conduct	Under investigation
20-01N	1/3/2020	Rovetti	Alleged unprofessional conduct-practicing below the standards of care/malpractice	Under investigation
20-03N	2/25/2020	Danielli:	Fellow to consider a third consider	Hadaa baas Radia
	2/26/2020	Rovetti	Failure to provide patient records	Under Investigation
20-04N	3/9/2020	Colucci	Alleged unlicensed practice	Recommend Dismissal
_				
20-10S	7/27/2020	Martinez	Alleged unprofessional conduct	Under Investigation
12-12 S	12/8/2020	Canada	Alleged unprofessional conduct	Under Investigation
	12/0/2020	Cullaua	Alleged disploitessional conduct	Under Investigation
20 126				
20-13S	12/9/2020	Colucci	Alleged unprofessional conduct	Under Investigation
20-14S	12/11/2020	Colucci	Alleged unprofessional conduct	Under Investigation
20-15N	12/11/2020	Canada	Allegedly practicing outside the scope of chiropractic	Under Investigation
D	ORMANT COMPLA		0/ F. sages 6 and active and sage of a mindproduct	

			To be held in abeyance; to be addressed
		Unredeemable "nsf" check written on Doctor's business account	if the licensee requests reinstatement in
11-23S	11/7/2011		the future
			To be held in abeyance; to be addressed
		Possible malpractice	if the licensee requests reinstatement in
13-23N	9/30/2013		the future
			Will be addressed if this individual
18-03S	2/20/2018	Alleged unlicensed practice	reappears in Nevada.

STATUS OF CURRENT DISCIPLINARY ACTIONS at January 14, 2021

Disciplinary Action with Probation

1. <u>Daniel Brady, DC, License No. B1391</u>

By Settlement Agreement, Dr. Brady shall comply with all terms and conditions of the California Board's Decision and Order dated April 24, 2012 (eff. May 24, 2012) which placed him on probation for five years with certain terms and conditions. He reimbursed the Board's \$325.00 costs on November 12, 2012 and passed the Board's jurisprudence examination with a score of 81%. Dr. Brady completed his probation in California, which satisfies the Nevada Board order. This will be the final reporting of Dr. Brady.

2. Casey D. Robinson, DC, License No. B1263

Dr. Robinson was granted a license on September 14, 2007 under the condition that he comply with all of the terms and conditions of his Agreement on Conditions for Licensure with California and monitoring of his practice by Board-appointed Compliance Monitor, Dr. Jeff Andrews. Dr. Robinson's 5-year probation with California commenced on February 14, 2006. He was required to reimburse the California Board's costs of \$3,103.75 and serve 4 hours per month of community service for 2-1/2 years of his probation. It was subsequently determined that Dr. Robinson did not comply with the terms and conditions of his agreement with California. This was addressed at the June 4, 2011 meeting and a new Agreed Settlement was approved that extends his probation for another five years concurrent with and under the same terms and conditions as his settlement agreement with California. Dr. Robinson was placed in tolling status effective November 18, 2015 and has a five-year tolling limit. Dr. Robinson is current and in compliance with the terms and conditions of his California probation per the California Board. Dr. Robinson let his license expire on 12/31/20.

3. Mark Rubin, DC, License No. B753

On September 10, 2016 Dr. Rubin entered into a Settlement Agreement and Order with the Board. Dr. Rubin will be on probation for three years with a practice monitor who will assure compliance with the terms and conditions of the settlement agreement. Dr. Rubin shall provide documentation as noted in the Settlement Agreement and Order to the Investigating Board Member within the time frames identified. Dr. Rubin was ordered to pay a fine in the amount of \$1,500.00 and pay the Board's costs in the amount of \$2,500.00.

Dr. Rubin appeared before the Board at its January 11, 2018 meeting and entered into an Order Modifying Settlement Agreement and Order. All the terms and conditions in the SAO entered September 10, 2016 shall remain in full force and effect, except he may pay the Board's costs at the minimum rate of \$50.00 per month and in lieu of paying the \$1,500.00 fine he may perform 100 hours of community service, which he has completed with the People's Autism Foundation. Dr. Rubin's probation terminated on September 10, 2019. The current balance of the Board costs due is \$500.00.

4. David Stella, DC, License No. B753

Dr. Stella entered an Order Imposing Discipline Pursuant to Supplemental Stipulation to Modify SAO on January 31, 2018. Dr. Stella will be on probation for three years effective January 31, 2018. Dr. Stella shall reimburse the Board \$2,500.00 for Dr. Mortillaro's fees within 30 days, which he paid on January 18, 2018. Dr. Stella shall pay a fine of \$3,500 (\$2,500.00 for the violation of his SAO and \$1,000.00 for violation of his recordkeeping obligations) and board costs & fees in the amount of \$1,280.00 within 60 days of the effective date of this order. Within six months of the effective date of this Order, Dr. Stella shall provide the Board's office written evidence of satisfactory completion of eight hours of continuing education related to ethics and boundaries and four hours related to medical recordkeeping. **Dr.**

Stella has completed all stipulations of the Order with the exception of probation, which terminates on January 31, 2021. This will be the final reporting of Dr. Stella.

5. <u>Daniel Camilleri, DC, License No. B01553</u>

On October 15, 2020 Dr. Daniel Camilleri entered into a Settlement Agreement and Order for failure to make and maintain legally sufficient patient records. Dr. Camilleri will be on probation and monitored by a practice monitor for one year, pay a fine in the amount of \$2,500.00 and Board costs in the amount of \$1,537.00, with 120 days take 12 hours of continuing education related to making and keeping medical records, and take and pass the Board's jurisprudence exam. To date Dr. Camilleri has satisfied all requirements with the exception of taking and passing the Nevada jurisprudence exam.

6. Michael Milman, DC, License No. B01618

On October 15, 2020 Dr. Michael Milman entered into Findings of Fact, Conclusions of Law, and Order with the Board. Dr. Milman will be on probation for five years with a practice monitor who will assure compliance with the terms and conditions of the Order. Dr. Milman was ordered to pay the Board's attorney fees and costs incurred in the investigation and prosecution of this matter totaling \$1,380.00. Dr. Milman must take and pass the Ethics & Boundaries Assessment. Dr. Milman shall maintain malpractice insurance, obtain and maintain all applicable business licensure, whether state, county, or city. Dr, Milman shall not bill any insurances, but work on a cash basis only and cannot accept personal injury cases. To date Dr. Milman has satisfied all requirements with the exception of taking and passing the EBAS.

Disciplinary Actions with No Probation

7. Francis Raines, DC, License No. B0187

Under the March 12, 2013 Board Order, Dr. Raines shall be monitored by the Investigating Board Member, a chiropractic physician, and a mental health monitor for 24 months from the date he begins practicing, which occurred on December 8, 2015. Dr. Raines' wife is serving as the business and financial manager and is currently the only employee. Dr. Raines was ordered to pay a fine in the amount of \$20,000.00 and has been making monthly payments of \$75.00 per month since May 30, 2013 and continues to do so. The current balance is \$14,471.00. Dr. Raines is in compliance with the terms of the Order.

David G. Rovetti, DC

5365 Mae Anne Avenue · Suite B-2 Reno, Nevada 89523

> Phone: (775) 324-3700 Toll free: (800) 324-3750 Fax: (775) 324-2370

Quarterly Report January 4^{th} , 2021

Xavier Martinez, DC CPBN 4600 Kietzke Lane, M245 Reno, NV 89502

RE: DANIEL CAMILLERI, DC

CASE #: 19-14N

MAXIMUM PROBATION PERIOD: 10/15/20 - 10/14/21

Dear Dr. Martinez,

The following is a synopsis of my monitoring of Dr. Camilleri:

I visited his office on 11/11/20 and on 12/22/20 and have reviewed a good sample of his patient notes. I also observed his practice as required in the Settlement Agreement.

After some initial difficulties with his computer program that wouldn't allow printing of his SOAP notes, he made a few changes to the location of where he imputed the notes on the screen, and adequate notes are now being produced. He makes several abbreviations in his notes but has developed a one-page "Key" that describes all the abbreviations one would see in his printed notes. All key components of NAC 634.435 are being met in the latest notes reviewed.

Dr. Camilleri has mentioned to his co-workers the way he does his notes now and has also mentioned the ramifications of keeping sub-par notes if the Board was to investigate.

Dr. Camilleri $\underline{\text{has}}$ completed the required 12 hours of CE on note taking. He has not yet $\underline{\text{taken}}$ and passed the Board's Law Test as of today.

I will continue to monitor his note-taking at least once next quarter.

Summary:

Notes appear to be adequate and in compliance with Nevada law and statutes. Further details and my worksheets are available upon request.

Q. Paretts, Tx

CHIROPRACTIC PHYSICIANS' BOARD

Legal/Investigatory Costs

		FY:	FY2020-2021			Year-To-Date	
Costs Incurred		Octo	ober to date		Fiscal Y	'ear 2020/2021	
Advantage Group						260.00	
Attorney General			1,080.53			1,080.53	
	Sub-Total		58.50			318.50	
Staff Attorney			1,065.00			7,155.00	
	Total	\$	1,123.50	\$ -	\$	7,473.50	
Costs Reimburse	Costs Reimbursed		YTD Amount Paid		Amount Owed		
Mark Rubin, DC		\$	2,000.00		\$	500.00	
James Overland Jr., DC		\$	7,570.98		\$	39,306.38	
Michael Milman, DC		\$	1,380.00		\$	-	
	Totals	\$	9,570.98	•	\$	39,806.38	
No Activity					C	Controller	
			-0-		\$	-	
		\$	-	- -	\$	-	

Other Outstanding Items:

CHIROPRACTIC PHYSICIANS' BOARD OF NEVADA TABLE OF CONTENTS

INDEPENDENT AUDITOR'S REPORT	3
BASIC FINANCIAL STATEMENTS:	
Statements of Net Position	5
Statements of Revenues, Expenses and Changes in Net Position	6
Statements of Cash Flows	7
Notes to Financial Statements	8
REQUIRED SUPPLEMENTARY INFORMATION:	
Budgetary Comparison Schedule	20
INDEPENDENT AUDITOR'S REPORT ON COMPLIANCE	22

BERTRAND & ASSOCIATES, LLC

CERTIFIED PUBLIC ACCOUNTANTS

Members American Institute of Certified Public Accountants

777 E. William St. Suite 206 Carson City, NV 89701 Tel 775.882.8892 Fax 775.562.2667

Email: Michael@bertrandcpa.com

INDEPENDENT AUDITOR'S REPORT

To the Executive Director and the Board of Directors Chiropractic Physicians' Board of Nevada Reno, Nevada

Report on the Financial Statements

We have audited the accompanying statements of net position of the Chiropractic Physicians' Board of Nevada as of June 30, 2020 and 2019 and the related statements of revenues and expenses and changes in net position and statements of cash flows for the years then ended, and the related notes to the financial statements, which collectively comprise the Board's basic financial statements as listed in the table of contents.

Management's Responsibility for the Financial Statements

Management is responsible for the preparation and fair presentation of these financial statements in accordance with accounting principles generally accepted in the United States of America; this includes the design, implementation, and maintenance of internal controls relevant to the preparation and fair presentation of financial statements that are free from material misstatement, whether due to fraud or error.

Auditor's Responsibility

Our responsibility is to express opinions on these financial statements based on our audit. We conducted our audit in accordance with auditing standards generally accepted in the United States of America. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free from material misstatement.

An audit involves performing procedures to obtain audit evidence about the amounts and disclosures in the financial statements. The procedures selected depend on the auditor's judgment, including the assessment of the risks of material misstatement of the financial statements, whether due to fraud or error. In making those risk assessments, the auditor considers internal controls relevant to the entity's preparation and fair presentation of the financial statements in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the entity's internal controls. Accordingly, we express no such opinion. An audit also includes evaluating the appropriateness of accounting policies used and the reasonableness of significant accounting estimates made by management, as well as evaluating the overall presentation of the financial statements.

We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinions.

Basis of qualified opinion

Beginning fiscal year ending June 30, 2018, Government Accounting Standards required certain adjustments to the financial statements and additional disclosures to account for and report on other postemployment benefits. Due to the additional costs to comply, management decided to not include those adjustments and disclosures with the financial statements. Quantification of the effects of the departure from U.S. Generally Accepted Accounting Principles on the financial statements of June 30, 2020 and June 30, 2019 is not practicable.

Qualified Opinion

In our opinion, except for the possible effects of the matter described in the Basis for Qualified Opinion paragraph, the financial statements referred to above present fairly, in all material respects, the respective financial positions of the business-type activities of Chiropractic Physicians' Board of Nevada as of June 30, 2020 and 2019 and the respective changes in financial position and cash flows for the years then ended in accordance with accounting principles generally accepted in the United States of America.

Other Matters

Required Supplementary Information

Accounting principles generally accepted in the United States of America requires the budgetary comparison and GASB required supplemental information be presented to supplement the basic financial statements. Such information, although not a part of the basic financial statements, is required by the Governmental Accounting Standards Board, who considers it to be an essential part of financial reporting for placing the basic financial statements in an appropriate operational, economic, or historical context. We have applied certain limited procedures to the required supplementary information in accordance with auditing standards generally accepted in the United States of America, which consisted of inquiries of management about the methods of preparing the information and comparing the information for consistency with management's responses to our inquiries, the basic financial statements, and other knowledge we obtained during our audit of the basic financial statements. We do not express an opinion or provide any assurance on the information because the limited procedures do not provide us with sufficient evidence to express an opinion or provide any assurance.

Management has omitted the management, discussion, and analysis that accounting principles generally accepted in the United States of America require to be presented to supplement the basic financial statements. Such missing information, although not a part of the basic financial statements, is required by the Governmental Accounting Standards Board, who considers it to be an essential part of financial reporting for placing the basic financial statements in an appropriate operational, economic, or historical context. Our opinion on the basic financial statements is not affected by this missing information.

Carson City, Nevada November 20, 2020

Bertrand & ASSOCIATES, LLC

CHIROPRACTIC PHYSICIANS' BOARD OF NEVADA STATEMENT OF NET POSITION June 30, 2020 and 2019

ASSETS	<u>2020</u>	<u>2019</u>
Current assets:		
Cash	\$ 547,313	\$ 722,915
Accounts receivable, net	63,753	66,628
Prepaid	4,511	5,453
Total current assets	615,577	794,996
Capital assets, net	-	-
Total noncurrent assets	-	
Total assets	615,577	794,996
DEFERRED OUTFLOWS OF RESOURCES		
Deferred outflows	45,981	48,892
LIABILITIES		
Current liabilities:		
Accounts payable	9,582	4,950
Due to State Treasurer	27,500	27,000
Funds held for refund	-	19,458
Payroll liabilities	2,067	1,831
Total current liabilities	39,149	53,239
Noncurrent liabilities:		
Compensated absences	12,936	9,529
PERS net pension liability	228,408	232,549
Total noncurrent liabilities	241,344	242,078
Total liabilities	280,493	295,317
DEFERRED INFLOWS OF RESOURCES		
Deferred inflows -pension	45,929	44,291
License fees	152,779	383,134
Total deferred inflows of resources	198,708	427,425
NET POSITION		
Invested in capital assets	-	-
Unrestricted	182,357_	121,146
Total net position	\$ 182,357	\$121,146

CHIROPRACTIC PHYSICIANS' BOARD OF NEVADA STATEMENT OF REVENUES, EXPENSES AND CHANGES IN NET POSITION For the years ended June 30, 2020 and 2019

Operating revenues:	2020	2019
Licensing fees	\$ 278,795	\$ 269,754
Other fees	70,711	54,420
Fines and other income	14,611	82,563
Total revenues	364,117	406,737
Operating expense:		
Salaries and benefits	164,593	152,616
Rent	14,670	14,550
General & Administrative	50,401	57,085
Professional	62,171	86,645
Travel	7,723	13,399
Board expense	3,631	5,693
Total operating expenses	303,189	329,988
Increase in operating net position	60,928	76,749
Increase in non-operating income - net investment income	283	21,720
Increase in net position	61,211	98,469
Net position at beginning of year, July 1	121,146	22,677
Net position at end of year, June 30	\$ 182,357	\$121,146

See notes to financial statement

CHIROPRACTIC PHYSICIANS' BOARD OF NEVADA STATEMENT OF CASH FLOWS

For the years ended June 30, 2020 and 2019

	<u>2020</u>	<u>2019</u>
CASH FLOWS FROM OPERATING ACTIVITIES:		
Receipts from licensees	\$ 138,275	\$ 588,816
Payments to vendors	(149,567)	(185,223)
Payments to employees	(121,338)	(112,004)
Payroll taxes & benefits paid	(43,255)	(40,612)
Total cash provided (used) from operating activities	(175,885)	250,977
CASH FLOWS FROM INVESTING ACTIVITIES:		
Sale of investments	-	160,800
Interest and dividends	283	795
Gain on sale of investments	-	20,925
Total cash provided from investing activities	283	182,520
Net increase (decrease) in cash	(175,602)	433,497
Beginning cash at June 30	722,915	289,418
Cash and Cash Equivalents at year's end, June 30	547,313	722,915

RECONCILIATION OF OPERATING INCOME TO NET CASH:

Adjustments to reconcile operating income to net cash provided by operating activities:

Operating net income	60,928	76,749
Decrease (increase) in net accounts receivables	2,875	(50,332)
Decrease in prepaid expense	972	441
Decrease in deferred outflows	2,911	547
Increase (decrease) in accounts payable	4,632	(1,087)
Increase (decrease) in payable due to state treasurer	500	(3,000)
Increase in payroll liabilities	236	53
Increase (decrease) in compensated absences	3,407	(2,797)
(Decrease) in funds held for refund	(19,458)	-
(Decrease) net pension liability	(4,141)	(2,008)
(Decrease) increase in deferred inflows	(228,717)	232,411
Net cash provided (used) by operating activities	\$ (175,855)	\$ 250,977

See notes to financial statement

CHIROPRACTIC PHYSICIANS' BOARD OF NEVADA NOTES TO FINANCIAL STATEMENTS

June 30, 2020 and 2019

NOTE 1 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

Background and Reporting Entity

The Chiropractic Physicians' Board of Nevada (Board) is comprised of seven members appointed by the governor as follows:

- One member who represents the interests of persons or agencies that regularly provide health care to patients who are indigent, uninsured or unable to afford health care.
- Four members who are:
 - Graduates of chiropractic schools or colleges.
 - Licensed by the Board; and
 - Actually engaged in the practice of chiropractic in the State and have been for at least three years prior to appointment.
- Two members who are representatives of the general public.

The accompanying financial statements of the Board have been prepared in conformity with accounting principles generally accepted in the United States of America (GAAP) as prescribed by the Governmental Accounting Standards Board (GASB). The Board has adopted Governmental Accounting Standards Board (GASB) Statement No. 62, Codification of Accounting and Financial Reporting Guidance Contained in Pre-November 30, 1989 FASB and AICPA Pronouncements as of January 1, 2012. Adoption of this standard had no impact on the Board's financial statements. The Board is not considered to be financially accountable for any other governmental entity since no other entities are considered to be controlled by or dependent on the Board. Control or dependence is determined on the basis of budget adoption, funding and appointment of the respective governing board.

Financial Statement Presentation

The Statements of Net Position; Revenues, Expenses and Changes in Net Position; and Cash Flows report information on all activities of the Board. The Board is reported as a single enterprise fund.

The Statement of Net Position presents the reporting entity's assets and liabilities, with differences reported as net assets. Net assets are reported in two categories:

Invested in capital assets consists of capital assets, net of accumulated depreciation. Capital assets of the Board have no related debt.

Unrestricted net position consists of net assets that do not meet the definition of the preceding category. Unrestricted net assets often have constraints on resources that are imposed by management but can be removed or modified.

The Statement of Revenues, Expenses and Changes in Net Position distinguishes operating revenues and expenses from non-operating items. Operating revenues and expenses generally result from providing services and producing and delivering goods in connection with the Board's principal ongoing operations. All revenues and expenses not meeting this definition are reported as non-operating revenues and expenses.

NOTE 1 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (continued)

Measurement Focus, Basis of Accounting

The financial statements are reported using the economic resources management focus and the accrual basis of accounting. Revenues are recorded when earned, and expenses are recorded when a liability is incurred, regardless of the timing of cash flows.

Cash and Equivalents

Cash balances are invested as permitted by law and insured by the Federal Deposit Insurance Corporation (FDIC) up to \$250,000. The Board considers all cash on hand as cash or cash equivalents.

Investments

Investments in marketable securities with readily determinable fair values and all investments in debt securities are reported at their fair values in the statements of net assets. Unrealized gains and losses are included in the change in net assets. The board does not have a formal policy regarding the kind of investments that they can invest in.

Accounts Receivable

Accounts receivable reflect license fees, cost, reimbursements and fines as a result of disciplinary actions. An allowance for doubtful accounts has been established which at year's end June 30, 2020 and 2019 were \$161,974 and \$164,693.

Accounts receivable are presented net of allowances for doubtful accounts. Management believes that accounts receivable that are over 90 days old net of allowances are collectible.

Capital Assets and Depreciation

All capital assets are recorded in the Statement of Net Position at historical cost. Fixed assets are fully depreciated as of yearend.

Donated capital assets are valued at their estimated fair value on the date of donation. The Board defines capital assets as assets with a unit cost of \$2,000 or more and an estimated useful life in excess of one year. Depreciation is accumulated on a straight-line basis over the estimated useful life of the asset, with one-half a year's depreciation taken in the year of acquisition and one-half in the final year. Useful life is estimated by management on the basis of their experience with similar assets.

Deferred Inflows of Resources - Revenues

Various licenses are billed for a two-year period resulting in unearned revenues at the end of the fiscal year. Deferred revenues represent amounts received but not earned as of year-end.

Use of Estimates

The Board uses estimates and assumptions in preparing the financial statements in conformity with accounting principles generally accepted in the United States of America. Those estimates and assumptions affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities, and the reported revenues and expenses. Actual results could differ from those estimates.

NOTE 1 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (continued)

Budgets and Budgetary Accounting

NRS 353.005 specifically exempts the Board from the requirements set forth in the State Budget Act. However, the Board prepares an annual budget for each fiscal year that is approved by a majority vote of the Board prior to the start of each fiscal year. The budget is used internally by the Board and staff and is prepared on the same basis as the financial statements.

Federal Income Taxes:

The Board is considered an exempt governmental agency in accordance with Internal Revenue Service Code Section 115. Therefore, income is excludable from gross income for federal income tax purposes.

Funds Held for Refund

The Board was holding \$19,458 in funds held for refund with regards to a disciplinary case. The chiropractor owes refunds to patients that he was unable to locate. The Board must hold the balance for three years pursuant to the Office of the Treasurer in the event these patients request their refund. The amount of \$19,458 was paid over the course of the year ending June 30, 2020.

Compensated Absences

Compensated absences are accounted for in accordance with GASB Statement No. 16, Accounting for Compensated Absences, which requires that a liability for compensated absences relating to services already tendered, and that are not contingent on a specified event, will be accounted for in the period when those services are rendered or those events take place. The Boards' policy provides for payment of accrued vacation time upon termination of employment if employed for six months or more, and a maximum payment of \$8,000 for sick leave upon termination of employment if employed ten years or more.

Prior Year Reclassifications

Prior year's financial statements have been reclassified where applicable to conform to the current year's presentation.

NOTE 2 – CASH & INVESTMENTS

On June 30, 2020 and 2019, cash and cash equivalents totaled \$547,313 and \$722,915 for deposits in a commercial bank. All funds are on deposit with a single financial institution and are carried at cost. The bank balances on June 30, 2020 and 2019 totaled \$544,311 and \$741,468. Bank balances are insured up to \$250,000 by the Federal Deposit Insurance Corporation and amounts in excess of the FDIC limit are collateralized by the bank.

NOTE 3 – RISK MANAGEMENT

The Board is exposed to various risks of loss related to tort, theft of, damage to, and destruction of assets; errors and omissions; and natural disasters, as are all entities. The Board is covered by commercial insurance purchased from independent third parties. There have been no claims from these risks during the years ended June 30, 2020 and 2019. Settled claims from these risks in the past have been minimal.

NOTE 4 – CAPITAL ASSETS

Depreciation is taken on the financial statements over the estimated useful lives of the assets using the straight-line method. It is believed by management that the useful lives of furniture and equipment range from five to ten years with no salvage value. When assets are disposed of the cost and related accumulated depreciation are removed from the general ledger and any resulting gain or loss is recognized in operations. There was no depreciation expense recorded for years ending June 30, 2020 and 2019.

	June	30, 2019	Addition	ıs	Dispositio	ons	June	30, 2020
Furniture and equipment	\$	16,501	\$	-	\$	-	\$	16,501
Accumulated depreciation	\$	(16,501)	\$	-	\$	-		(16,501)
Net equipment	\$	-	\$	-	\$	-	\$	-
	June	30, 2018	Addition	ıs	Dispositio	ons	June	30, 2019
Furniture and equipment	June \$	30, 2018 16,501	Addition \$	1S		ons -	June \$	30, 2019 16,501
Furniture and equipment Accumulated depreciation					<u> </u>			

NOTE 5 – POST RETIREMENT BENEFITS

Some employees of the Board are entitled to post-retirement health care benefits from the State of Nevada. The Board pays an assessment to fund these future benefits at a rate determined by the State Department of Administration. The rate of assessment was 2.34% and \$761 per employee per month in 2020 and 2.34% and \$741 per employee in 2019. The total amounts paid for years ended 2020 and 2019 were \$19,366 and \$22,411.

The Government Accounting Standards Board issued Statement 75 which provides guidance on how other post-retirement benefits are to be reported along with footnoted disclosures. Management has not implemented this new statement.

NOTE 6 – OPERATING LEASES

The Board is obligated under operating leases for office space and a postage meter, expiring on various dates through 2026. The postage meter, at the end of the lease term, is renewable at its fair rental values. The office lease was renewed for a five-year term beginning November 1, 2020. The minimum rental commitments under the operating leases are as follows:

For years ended	June 30,	
	2021	\$ 10,246
	2022	15,266
	2023	15,159
	2024	14,952
	2025	15,060
	2026	5,020
		\$ 75,703

The expense for all operating leases for years ended June 30, 2020 and 2019 was \$12,734 and \$18,109 respectively.

NOTE 7 – DEFINED BENEFIT PENSION COST-SHARING EMPLOYER PLAN

A. General Information about the Pension Plan

<u>Plan Description</u> – All qualified permanent and probationary employees are eligible to participate in the Board's Employee Pension Plans, cost-sharing multiple employer defined benefit pension plans administered by the Public Employees' Retirement System of Nevada (PERS). Benefit provisions under the Plans are established by State statute and Board resolution. PERS issues publicly available reports that include a full description of the pension plans regarding benefit provisions, assumptions and membership information that can be found on the PRS website.

<u>Benefits Provided</u> – PERS provides service based retirement and disability benefits, annual cost of living adjustments and death benefits to plan members, who must be public employees and beneficiaries. Benefits are based on years of credited service, equal to one year of full-time employment.

NOTE 7 – DEFINED BENEFIT PENSION COST-SHARING EMPLOYER PLAN (continued)

The Plans' provisions and benefits in effect on June 30, 2020 are summarized as follows:

	Prior to	Between July 1, 2001	Between January 1, 2010	On or after
Hire date	<u>July 1, 2001</u>	and January 1, 2010	and July 1, 2015	<u>July 1, 2015</u>
Benefit formula	2.50%	2.67%	2.50%	2.25%
Benefit vesting option 1	5 years service @65	5 years service @65	5 years service @65	5 years service @65
Benefit vesting option 2	10 years service @60	10 years service @60	10 years service @62	10 years service @62
Benefit vesting option 3	any age with 30 years	any age with 30 years	any age with 30 years	
	service	service	service	30 years service @55
Benefit payments	monthly for life	monthly for life	monthly for life	monthly for life
Retirement age	50-55	52-67	52-67	52-67
Monthly benefits as a % of eligible	2.50%	2.67%	2.50%	2.25%
Required employer contributions				
rates	unavailable	unavailable - 21.5%	28%	28%

Contributions – The contributions are made in accordance with the required rates established by the Nevada Legislature. These statutory rates are increased/decreased pursuant to NRS 286.421 and 286.450. Funding contributions for the Plans are determined bi- annually on an actuarial basis as of June 30 by PERS. The actuarially determined rate is the estimated amount necessary to finance the costs of benefits earned by employees during the year, with an additional amount to finance any unfunded accrued liability. The Board is required to contribute the difference between the actuarially determined rate and the contribution rate of employees.

For the year ended June 30, 2020, the contributions recognized as part of pension expense for the Plan were as follows:

Contributions - employer

\$22,782

B. Pension Liabilities, Pension Expenses and Deferred outflows/Inflows of Resources Related to Pensions

As of June 30, 2020, the Board reported net pension liabilities for its proportionate shares of the net pension liability of the Plan as follows:

Proportionate share of net pension liability \$228,408

Miscellaneous plan

NOTE 7 – DEFINED BENEFIT PENSION COST-SHARING EMPLOYER PLAN (continued)

The Board's net pension liability for the Plan is measured as the proportionate share of the net pension liability. The net pension liability of the Plan is measured as of June 30, 2019, and the total pension liability for the Plan used to calculate the net pension liability was determined by an actuarial valuation as of June 30, 2019. The Board's proportion of the net pension liability was based on a projection of the Board's long-term share of contributions to the pension plan relative to the projected contributions of all participating employers, actuarially determined.

The Board's proportionate share of the net pension liability as of June 30, 2018 and 2019 was as follows:

Proportion - June 30, 2018	0.00171%
Proportion - June 30, 2019	0.00168%
Change: Increase -Decrease	-0.00003%

For the year ended June 30, 2020, the Board recognized a pension expense of \$20,164. At June 30, 2020, the Board reported deferred outflows of resources and deferred inflows of resources related to pensions from the following sources:

	Def	Ferred Outflows of Resources	Deferred Inflows of Resources
Differences between expected and actual experience	\$	1,280	\$ 4,206
Changes in assumptions		(2,959)	_
Net difference between projected and actual earnings on pension plan investments		-	(10,255)
Changes in proportion and differences between Board contributions and proportionate share of contributions		24,878	51,978
Board contributions subsequent to the measurement date		22,782	-
Total	\$	45,981	\$ 45,929

NOTE 7 – DEFINED BENEFIT PENSION COST-SHARING EMPLOYER PLAN (continued)

\$22,782 reported as deferred outflows of resources related to contributions to NVPERS subsequent to the measurement date will be recognized as a reduction of the net pension liability in the year ended June 30, 2020. Other amounts reported as deferred outflows of resources and deferred inflows of resources related to pensions will be recognized as pension expense as follows:

Measurement Period		
Ended June 30:	_	
2021	\$	657
2022		(4,424)
2023		1,215
2024		1,506
2025		856
2026		22,822
Thereafter		-
Total	\$	22,632

<u>Actuarial Assumptions</u> – The total pension liabilities in the June 30, 2019 actuarial valuations were determined using the following actuarial assumptions:

	Miscellaneous
Valuation date	June 30, 2019
Measurement date	June 30, 2019
Actuarial Cost Method	Entry -Age Normal Cost
Actuarial Assumptions:	
Productivity pay increases	0.50%
Inflation	2.75%
Payroll growth	5.00%
Projected salary increase	4.25% - 9.15%
Investment rate of return	7.50%

The underlying mortality assumptions and all other actuarial assumptions used in the June 30, 2019 valuation were based on the results of the experience review completed in 2019. Further details of the Experience Study can be found on the PERS website.

Discount Rate – The discount rate used to measure the total pension liability was 7.50% as of June 30, 2019. The projection of cash flows used to determine the discount rate assumed that employee and employer contributions will be made at the rate specified in statute. Based on that assumption, the pension

NOTE 7 – DEFINED BENEFIT PENSION COST-SHARING EMPLOYER PLAN (continued)

plan's fiduciary net position on June 30, 2019, was projected to be available to make all projected future benefit payments of current active and inactive employees. Therefore, the long-term expected rate of return on pension plan investments was applied to all periods of projected benefit payments to determine the total pension liability as of June 30, 2019.

The System's Investment Objectives and Policies detail the fund's long-term investment goals, management responsibilities, return/risk expectations, and monitoring requirements. These policies are subject to change at any time by the Board and are reviewed thoroughly at least annually to ensure that they continue to reflect the System's expectations.

To establish an appropriate long-term asset allocation strategy, the Board evaluates expected return and risk for each of the major asset types (stocks, bonds, private markets). These asset classes are then combined in the most efficient manner possible to construct a portfolio that matches the risk and return needs of the fund. By diversifying the System's investments in multiple asset classes, the Board is able to reduce the volatility of annual investment earnings. The Board reviews capital market expectations and asset allocation annually. In addition, the Board employs a disciplined rebalancing policy to manage market volatility and to ensure the portfolio's exposures are consistent with the System's long-term asset targets.

Additional information on the discount rate, investment strategy and diversification is available in the PERS CAFR which can be found at www.nvpers.org.

The System's policies which determine the investment portfolio target asset allocation is established by the Board. The asset allocation is reviewed annually and is designed to meet the future risk and return needs of the System.

The following was the Board adopted policy target asset allocation as of June 30, 2019:

	Target	Long-Term Geometric
Asset Class	Allocation	Expected Real Rate of Return*
Domestic Equity	42%	5.50%
International Equity	18%	5.50%
Domestic Fixed Incom	28%	0.75%
Private Markets	12%	6.65%

^{*}As of June 30, 2019, PERS' long-term inflation assumption was 2.75%

NOTE 7 – DEFINED BENEFIT PENSION COST-SHARING EMPLOYER PLAN (continued)

Sensitivity of the Proportionate Share of the Net Pension Liability to Changes in the Discount Rate — The following presents the net pension liability of the PERS as of June 30, 2020, calculated using the discount rate of 7.50%, as well as what the PERS net pension liability would be if it were calculated using a discount rate that is 1-percentage-point lower (6.5%) or 1-percentage-point higher (8.5%) than the current discount rate:

	Discount rate -1%	Current Discount	Discount Rate +1%
	(6.5%)	Rate (7.5%)	(8.5%)
Misc. Tier1	\$354,709	\$228,408	\$124,658

NOTE 8 – LICENSE RENEWALS

Revenues and deferred inflows for licenses issued were reported for the years ended June 30, 2020 and 2019. Doctor of Chiropractic licenses were granted for a 2-year period and licenses were renewed for the periods beginning January 1, 2019.

Chiropractor's Assistant certificates were issued for a 2-year period starting January 1, 2018 and again January 1, 2020.

NOTE 9 – SUBSEQUENT EVENTS

On March 17, 2020 the Governor of Nevada declared a health emergency and issued an order to close all nonessential businesses until further notice. In response, the Board implemented a remote work policy, as well as an adjusted in-office schedule for employees that has continued to the present. Not all Board functions are digitize3d which requires staff to physically work from the Board office. While the Board expects this matter to potentially have an impact to its operations, cash flows and financial position, the related impact cannot be reasonably estimated at this time.

Management has evaluated the activities and transactions subsequent to June 30, 2020 to determine the need for any adjustments to, and disclosure within the financial statements for the year ended June 30, 2020. Management has evaluated subsequent events through November 20, 2020, which is the date the financial statements were available for issue.

CHIROPRACTIC PHYSICIANS' BOARD OF NEVADA REQUIRED SUPPLEMENTARY INFORMATION SCHEDULE OF THE BOARD'S PROPORTIONATE SHARE OF THE NET PENSION LIABILITY LAST TEN YEARS

				Board's proportionate	
				share of the net	Plan fiduciary
	Board's	Board's		pension liability (asset)	net position as a
	proportion of	proportionate share		as a percentage of its	percentage of
Actuarial	the net pension	of the net pension	Board's covered -	covered-employee	the total pension
Valuation Date	liability (asset)	liability (asset)	employee payroll	payroll	liability
6/30/2019	0.00168%	\$228,408	\$141,855	161.01%	76.5%
6/30/2018	0.00171%	\$232,549	\$138,800	167.54%	75.1%
6/30/2017	0.00176%	\$234,557	\$139,214	168.49%	74.5%
6/30/2016	0.00194%	\$260,992	\$137,562	189.73%	74.1%
6/30/2015	0.00208%	\$238,870	\$121,411	196.74%	73.2%
6/30/2014	0.00191%	\$199,307	\$109,306	182.34%	76.3%

This information is required by the Governmental Accounting Standards Board

CHIROPRACTIC PHYSICIANS' BOARD OF NEVADA REQUIRED SUPPLEMENTARY INFORMATION SCHEDULE OF THE BOARD'S CONTRIBUTIONS - LAST TEN YEARS

	Contractually	Contribution in relation	Contribution		Contributions as a
	required	to the contractually	deficiency	Board's covered	percentage of covered
Actuarial Valuation Date	contribution	required contribution	(excess)	employee payroll	employee payroll
6/30/2020	\$39,512	(\$39,512)	\$0	\$129,548	30.50%
6/30/2019	\$41,138	(\$41,138)	\$0	\$141,855	29.00%
6/30/2018	\$40,252	(\$40,252)	\$0	\$138,800	29.00%
6/30/2017	\$40,372	(\$40,372)	\$0	\$139,214	29.00%
6/30/2016	\$36,454	(\$36,454)	\$0	\$137,562	26.50%
6/30/2015	\$32,174	(\$32,174)	\$0	\$121,411	26.50%

This information is required by the Governmental Accounting Standards Board

CHIROPRACTIC PHYSICIANS' BOARD OF NEVADA BUDGETARY COMPARISON SCHEDULE

For the Year Ended June 30, 2020

	Original			
Revenues	Budget	Final Budget	Actual	Variance
Licensing fees	\$ 256,850	\$ 256,850	\$ 278,795	\$ 21,945
Other fees	58,060	58,060	70,711	12,651
Fines and other income	12,674	12,674	14,611	1,937
Total revenues	327,584	327,584	364,117	36,533
Expenses				
Salaries & benefits	168,912	168,912	164,593	4,319
Rent	14,816	14,816	14,670	146
General & administrative	61,205	61,205	50,401	10,804
Professional	67,081	67,081	62,171	4,910
Travel	14,816	14,816	7,723	7,093
Board expense	8,115	8,115	3,631	4,484
Total expenditures	334,945	334,945	303,189	31,756
Excess of revenues over (under) expenditures	(7,361)	(7,361)	60,928	68,289
Unrestricted net position, July 1,	22,677	22,677	121,146	98,469
Increase in non-operating income	-	-	283	283
Unrestricted net position, June 30	\$ 15,316	\$ 15,316	\$ 182,357	\$ 167,041

See notes to financial statements

COMPLIANCE

AUDITOR'S REPORT ON COMPLIANCE WITH NEVADA REVISED STATUTES AND CHIROPRACTIC PHYSICIANS' BOARD OF NEVADA

To the Members Chiropractic Physicians' Board of Nevada

I have audited the entity wide financial statements of the Chiropractic Physicians' Board of Nevada (Board), as of and for the year ended June 30, 2020, and have issued my report thereon dated November 20, 2020. I conducted my audit in accordance with United States generally accepted auditing standards.

Compliance

As part of obtaining reasonable assurance about whether the Chiropractic Physicians' Board of Nevada financial statements are free of material misstatement, I performed tests of its compliance with certain provisions of laws, regulations, contracts, and grants, noncompliance with which could have a direct and material effect on the determination of financial statement amounts. Compliance with Nevada Revised Statutes (NRS) and regulations (Nevada Administrative Code) applicable to the Chiropractic Physicians' Board of Nevada is the responsibility of the Board's management. Providing an opinion on compliance with those provisions was not an objective of my audit, and accordingly, I do not express such an opinion. In connection with my audit, nothing came to my attention that caused me to believe the Board had not complied with NRS 634 and other Nevada Revised Statutes and regulations, insofar as they relate to accounting matters.

This report is intended solely for the information and use of the Board of Directors, management and others within the organization and the Nevada Legislative Counsel Bureau. This restriction is not intended to limit distribution of this report, which is a matter of public record.

Carson City, Nevada November 20, 2020

Bertrand & ASSOCIATES, LLC

BERTRAND & ASSOCIATES, LLC

CERTIFIED PUBLIC ACCOUNTANTS

Members American Institute of Certified Public Accountants

November 20, 2020

Julie Strandberg, Executive Director Chiropractic Physicians' Board of Nevada 4600 Kietzke Lane, Suite M245 Reno, NV 89502 777 E. William St Suite 206 Carson City, NV 89701 Tel 775.882.8892 Fax 775.562.2667

RE: Proposal and engagement letter for June 30, 2021 and 2022 audits

Dear Ms. Strandberg:

We are pleased to propose and if accepted, confirm our understanding of the services we are to provide Chiropractic Physicians' Board of Nevada (Board) for the year ended June 30, 2021. We will audit the statement of net assets, statement of revenues, expenses, statement of changes in fund net assets and statement of cash flows of the Board as of June 30, 2021. This proposal and engagement letter will be for the audit of the years ended June 30, 2021 and 2022.

Accounting standards generally accepted in the United States provide for certain required supplementary information (RSI), such as management's discussion and analysis (MD&A), to accompany the Board's basic financial statements. As per your request, we will not include an MD & A or the GASB 75 adjustments and disclosures which will result in a modification of our report letter. GASB 68 requires supplementary schedules (RSI) and as part of our engagement, we will apply certain limited procedures to the Board's RSI. These limited procedures will consist principally of inquiries of the PERS actuary's report regarding the methods of measurement and presentation, which management is responsible for affirming to us in its representation letter. Unless we encounter problems with the presentation of the RSI or with procedures relating to it, we will disclaim an opinion on it. The following RSI is required by generally accepted accounting principles and will be subjected to certain limited procedures and not be audited (GASB 68) or not be included.

- 1. Management's Discussion and Analysis. (not included)
- 2. GASB 68 required supplementary schedules
- 3. GASB 75 supplementary schedules. (not included)

Audit Objective

The objective of our audit is the expression of opinions as to whether your basic financial statements are fairly presented, in all material respects, in conformity with U.S. generally accepted accounting principles. Our audit will be conducted in accordance with U.S. generally accepted auditing standards and will include tests of the accounting records and other procedures we consider necessary to enable us to express such an opinion. If our opinions on the financial statements are other than unqualified, we will fully discuss the reasons with you in advance.

We anticipate a qualified opinion as a new accounting standard known as GASB 75 will not be applied as the Public Employees Benefits Program (PEBP) will not provide the needed actuarial information and it is our understanding that the Board will not seek to incur the expense to hire an actuarial consultant. If, for any reason, we are unable to complete the audit or are unable to form or have not formed opinions, we may decline to express opinions or to issue a report as a result of this engagement.

Management Responsibilities

Management is responsible for establishing and maintaining internal controls, including monitoring ongoing activities; for the selection and application of accounting principles; and for the fair presentation in the financial statements of the respective financial position of the governmental activities, the business-type activities, the aggregate discretely presented component units, each major fund, and the aggregate remaining fund information of the Nevada Association of Counties and the respective changes in financial position and where applicable, cash flows, in conformity with U.S. generally accepted accounting principles. Management is responsible for the basic financial statements and all accompanying information as well as all representations contained therein. You are also responsible for management decisions and functions; for designating an individual with suitable skill, knowledge, or experience to oversee our financial statement preparation services and any other non-attest services we provide; and for evaluating the adequacy and results of those services and accepting responsibility for them.

Management is responsible for making all financial records and related information available to us and for the accuracy and completeness of that information. Management is responsible for adjusting the financial statements to correct material misstatements and for confirming to us in the representation letter that the effects of any uncorrected misstatements aggregated by us during the current engagement and pertaining to the latest period presented are immaterial, both individually and in the aggregate, to the financial statements taken as a whole.

You are responsible for the design and implementation of programs and controls to prevent and detect fraud, and for informing us about all known or suspected fraud or illegal acts affecting the government involving (1) management, (2) employees who have significant roles in internal control, and (3) others where the fraud or illegal acts could have a material effect on the financial statements. Your responsibilities include informing us of your knowledge of any allegations of fraud or suspected fraud affecting the government received in communications from employees, former employees, regulators, or others. In addition, you are responsible for identifying and ensuring that the entity complies with applicable laws and regulations.

Audit Procedures—Internal Control

Our audit will include obtaining an understanding of the government and its environment, including internal control, sufficient to assess the risks of material misstatement of the financial statements and to design the nature, timing, and extent of further audit procedures. An audit is not designed to provide assurance on internal control or to identify deficiencies in internal control. However, during the audit, we will communicate to management and those charged with governance internal control related matters that are required to be communicated under AICPA professional standards.

Audit Procedures—Compliance

As part of obtaining reasonable assurance about whether the financial statements are free of material misstatement, we will perform tests of the Board's compliance with the provisions of applicable laws, regulations, contracts, and agreements. However, the objective of our audit will not be to provide an opinion on overall compliance, and we will not express such an opinion.

Audit Procedures-General

Our procedures will include tests of documentary evidence supporting the transactions recorded in the accounts and may include tests of the physical existence of inventories, and direct confirmation of receivables and certain other assets and liabilities by correspondence with selected individuals, creditors, and financial institutions. We will request written representations from your attorneys as part of the engagement, and they may bill you for responding to this Inquiry. At the conclusion of our audit, we will also require certain written representations from you about the financial statements and related matters.

An audit includes examining, on a test basis, evidence supporting the amounts and disclosures in the financial statements; therefore, our audit will involve judgment about the number of transactions to be examined and the areas to be tested. We will plan and perform the audit to obtain reasonable rather than absolute assurance about whether the financial statements are free of material misstatement, whether from (1) errors, (2) fraudulent financial reporting, (3) misappropriation of assets, or (4) violations of laws or governmental regulations that are attributable to the entity or to acts by management or employees acting on behalf of the entity.

Because an audit is designed to provide reasonable, but not absolute, assurance and because we will not perform a detailed examination of all transactions, there is a risk that material misstatements may exist and not be detected by us. In addition, an audit is not designed to detect immaterial misstatements, or violations of laws or governmental regulations that do not have a direct and material effect on the financial statements. However, we will inform you of any material errors and any fraudulent financial reporting or misappropriation of assets than come to our attention. We will also inform you of any violations of laws or governmental regulations that come to our attention, unless clearly inconsequential. Our responsibility as auditors are limited to the period covered by our audit and does not extend to any later periods for which we are not engaged as auditors.

Other Services

We will assist you in the preparation of the notes to the financial statements and the adjustment for the GASB 68 pension liability and related notes which will primarily be derived from the actuary's report. These are non-attest services that we will provide. We will prepare the services in accordance with applicable professional standards. You are responsible to oversee this service and have competent staff to review our work performed and evaluate the adequacy and results of this service. We may discover corrections to the financial statements that we may not propose that you record and will review those with you or your staff. You agree that you will accept responsibility for these services.

Engagement Administration, Fees, and Other

Michael Bertrand is the engagement partner and is responsible for supervising the engagement and signing the report. Our retention policy is to retain audit work papers for seven years after

the close of the audited year. We understand that your employees will prepare all cash or other confirmations and schedules we request and will locate any documents selected by us for testing.

We expect to begin our audit on approximately July 25, 2021 and to issue our reports no later than December 1, 2021. Our fee for these services will be at our standard hourly rates plus out-of-pocket costs (such as increased insurance coverage you may require, report reproduction, word processing, postage, travel, copies, etc.) and expect the fee to be \$6,100. Our standard hourly rates vary according to the degree of responsibility involved and the experience level of the personnel assigned to your audit. Our invoices for these fees will be rendered as work progresses and are payable on presentation. In accordance with our firm policies, work may be suspended if your account becomes nonpayment, our engagement will be deemed to have been completed upon written notification of termination, even if we have not completed our report. You will be obligated to compensate us for all time expended and to reimburse us for all out-of-pocket costs through the date of termination.

The above fee is based on anticipated cooperation from your personnel and in their providing requested information timely and the assumption that unexpected circumstances will not be encountered during the audit. If significant additional time is necessary; we will discuss it with you and arrive at a new fee estimate before we incur the additional costs. Based on a reoccurrence of prior year experience we would estimate those additional costs at \$300.

We appreciate the opportunity to be of service to the Board and believe this letter accurately summarizes the significant terms of our engagement. If you have any questions, please let us know. If you agree with the terms of our engagement as described in this letter, please sign the enclosed copy and return it to us.

Very truly yours,

3.4" 1 1	т .	D .	1
Michael		Bertrar	าส

Bertrand & Associates, LLC

Middel J. Bertral

RESPONSE:

This letter correctly sets forth the understanding of the Board

By: ______

Title: _____

Date: _____

CETS #:	
Solicitation #:	

CONTRACT FOR SERVICES OF INDEPENDENT CONTRACTOR FOR LESS THAN \$50,000

A Contract Between the State of Nevada Acting by and Through its

Agency Name:	Chiropractic Physicians' Board of Nevada	
Address:	4600 Kietzke Lane, Suite M245	
City, State, Zip Code:	Reno, NV 89502	
Contact:	Julie Strandberg, Executive Director	
Phone:	775-688-1923	
Fax:	775-688-1920	
Email:	chirobd@chirobd.nv.gov	

Contractor Name:	Bertrand & Associates, LLC
Address:	777 E. Williams Street, Suite 206
City, State, Zip Code:	Carson City, NV 89701
Contact:	Michael Bertrand
Phone:	775-882-8892
Fax:	775-562-2667
Email:	michael@bertrandcpa.com

WHEREAS, NRS 333.700 authorizes officers, departments, institutions, boards, commissions, and other agencies in the Executive Branch of the State Government which derive their support from public money in whole or in part to engage services of persons as independent contractors; and

WHEREAS, it is deemed that the service of Contractor is both necessary and in the best interests of the State of Nevada.

NOW, THEREFORE, in consideration of the aforesaid premises, the parties mutually agree as follows:

1. **CONTRACT TERM.** This Contract shall be effective as noted below, unless sooner terminated by either party as specified in *Section 7*, *Contract Termination*. Contracts requiring approval of the Nevada Board of Examiners or the Clerk of the Board are not effective until such approval has occurred, however, after such approval, the effective date will be the date noted below.

Effective from:	Upon Approval	To:	December 31, 2022

2. **NOTICE.** All communications, including notices, required or permitted to be given under this Contract shall be in writing and directed to the parties at the addresses stated above. Notices may be given: (a) by delivery in person; (b) by a nationally recognized next day courier service, return receipt requested; or (c) by certified mail, return receipt requested. If specifically requested by the party to be notified, valid notice may be given by facsimile transmission or email to the address(es) such party has specified in writing.

CETS #:	
Solicitation #:	

3. **SCOPE OF WORK**. The Scope of Work is described below, which is incorporated herein by reference:

DESCRIPTION OF SCOPE OF WORK:	
This is a new contract to provide audit services on an annual basis.	

An Attachment must be limited to the Scope of Work to be performed by Contractor. Any provision, term or condition of an Attachment that contradicts the terms of this Contract, or that would change the obligations of the State under this Contract, shall be void and unenforceable.

4. **CONSIDERATION**. The parties agree that Contractor will provide the services specified in *Section 3*, *Scope of Work* at a cost as noted below:

\$6,100.00		per	year
Total Contract or installments payable at:			
Total Contract Not to Exceed: \$12,800.00			

The State does not agree to reimburse Contractor for expenses unless otherwise specified in the Scope of Work or incorporated Attachments (if any). Any intervening end to a biennial appropriation period shall be deemed an automatic renewal (not changing the overall Contract term) or a termination as the result of legislative appropriation may require.

- 5. **BILLING SUBMISSION: TIMELINESS.** The parties agree that timeliness of billing is of the essence to the Contract and recognize that the State is on a Fiscal Year. All billings for dates of service prior to July 1 must be submitted to the State no later than the first Friday in August of the same calendar year. A billing submitted after the first Friday in August, which forces the State to process the billing as a stale claim pursuant to NRS 353.097, will subject Contractor to an administrative fee not to exceed one hundred dollars (\$100.00). The parties hereby agree this is a reasonable estimate of the additional costs to the State of processing the billing as a stale claim and that this amount will be deducted from the stale claim payment due to Contractor.
- 6. **INSPECTION & AUDIT.** Contractor agrees to keep and maintain under generally accepted accounting principles (GAAP) and as required by State and federal law, complete and accurate records as are necessary to fully disclose to the State or United States Government, sufficient information to determine compliance with all State and federal regulations and statutes, and compliance with the terms of this contract, and agrees that such documents will be made available for inspection upon reasonable notice from authorized representatives of the State or Federal Government.

7. **CONTRACT TERMINATION.**

- A. <u>Termination Without Cause</u>. Regardless of any terms to the contrary, this Contract may be terminated upon written notice by mutual consent of both parties. The State unilaterally may terminate this contract without cause by giving not less than thirty (30) days' notice in the manner specified in *Section 2, Notice*. If this Contract is unilaterally terminated by the State, Contractor shall use its best efforts to minimize cost to the State and Contractor will not be paid for any cost that Contractor could have avoided.
- B. State Termination for Non-Appropriation. The continuation of this Contract beyond the current biennium is subject to and contingent upon sufficient funds being appropriated, budgeted, and otherwise made available by the State Legislature and/or federal sources. The State may terminate this Contract, and Contractor waives any and all claims(s) for damages, effective immediately upon receipt of written notice (or any date specified therein) if for any reason the Contracting Agency's funding from State and/or federal sources is not appropriated or is withdrawn, limited, or impaired.
- C. <u>Termination with Cause for Breach</u>. A breach may be declared with or without termination. A notice of breach and termination shall specify the date of termination of the Contract, which shall not be sooner than the expiration of the

CETS#:	
Solicitation #:	

Time to Correct, if applicable, allowed under *Subsection 7D*. This Contract may be terminated by either party upon written notice of breach to the other party on the following grounds:

- 1) If Contractor fails to provide or satisfactorily perform any of the conditions, work, deliverables, goods, or services called for by this Contract within the time requirements specified in this Contract or within any granted extension of those time requirements; or
- 2) If any state, county, city, or federal license, authorization, waiver, permit, qualification or certification required by statute, ordinance, law, or regulation to be held by Contractor to provide the goods or services required by this Contract is for any reason denied, revoked, debarred, excluded, terminated, suspended, lapsed, or not renewed; or
- 3) If Contractor becomes insolvent, subject to receivership, or becomes voluntarily or involuntarily subject to the jurisdiction of the Bankruptcy Court; or
- 4) If the State materially breaches any material duty under this Contract and any such breach impairs Contractor's ability to perform; or
- 5) If it is found by the State that any quid pro quo or gratuities in the form of money, services, entertainment, gifts, or otherwise were offered or given by Contractor, or any agent or representative of Contractor, to any officer or employee of the State of Nevada with a view toward securing a contract or securing favorable treatment with respect to awarding, extending, amending, or making any determination with respect to the performing of such contract; or
- 6) If it is found by the State that Contractor has failed to disclose any material conflict of interest relative to the performance of this Contract.
- D. <u>Time to Correct</u>. Unless the breach is not curable, or unless circumstances do not permit an opportunity to cure, termination upon declared breach may be exercised only after service of formal written notice as specified in *Section 2, Notice*, and the subsequent failure of the breaching party within fifteen (15) calendar days of receipt of that notice to provide evidence, satisfactory to the aggrieved party, showing that the declared breach has been corrected. Upon a notice of breach, the time to correct and the time for termination of the contract upon breach under *Subsection 7C*, above, shall run concurrently, unless the notice expressly states otherwise.
- 8. **REMEDIES**. Except as otherwise provided for by law or this Contract, the rights and remedies of the parties shall not be exclusive and are in addition to any other rights and remedies provided by law or equity, including, without limitation, actual damages, and to a prevailing party reasonable attorneys' fees and costs. For purposes of an award of attorneys' fees to either party, the parties stipulate and agree that a reasonable hourly rate of attorneys' fees shall be one hundred and fifty dollars (\$150.00) per hour. The State may set off consideration against any unpaid obligation of Contractor to any State agency in accordance with NRS 353C.190. In the event that Contractor voluntarily or involuntarily becomes subject to the jurisdiction of the Bankruptcy Court, the State may set off consideration against any unpaid obligation of Contractor to the State or its agencies, to the extent allowed by bankruptcy law, without regard to whether the procedures of NRS 353C.190 have been utilized.
- 9. **LIMITED LIABILITY**. The State will not waive and intends to assert available NRS Chapter 41 liability limitations in all cases. Contract liability of both parties shall not be subject to punitive damages. Damages for any State breach shall never exceed the amount of funds appropriated for payment under this Contract, but not yet paid to Contractor, for the Fiscal Year budget in existence at the time of the breach. Contractor's tort liability shall not be limited.
- 10. INDEMNIFICATION AND DEFENSE. To the fullest extent permitted by law, Contractor shall indemnify, hold harmless and defend, not excluding the State's right to participate, the State from and against all liability, claims, actions, damages, losses, and expenses, including, without limitation, reasonable attorneys' fees and costs, arising out of any breach of the obligations of Contractor under this Contract, or any alleged negligent or willful acts or omissions of Contractor, its officers, employees and agents. Contractor's obligation to indemnify the State shall apply in all cases except for claims arising solely from the State's own negligence or willful misconduct. Contractor waives any rights of subrogation against the State. Contractor's duty to defend begins when the State requests defense of any claim arising from this Contract.

CETS #:	
Solicitation #:	

- 11. **REPRESENTATIONS REGARDING INDEPENDENT CONTRACTOR STATUS.** Contractor represents that it is an independent contractor, as defined in NRS 333.700(2) and 616A.255, warrants that it will perform all work under this contract as an independent contractor, and warrants that the State of Nevada will not incur any employment liability by reason of this Contract or the work to be performed under this Contract. To the extent the State incurs any employment liability for the work under this Contract; Contractor will reimburse the State for that liability.
- 12. **INSURANCE SCHEDULE.** Unless expressly waived in writing by the Contracting Agency, Contractor must procure, maintain and keep in force for the duration of the Contract insurance conforming to the minimum requirements specified below. Each insurance policy shall provide for a waiver of subrogation against the State of Nevada, its officers, employees and immune contractors as defined in NRS 41.0307, for losses arising from work/materials/equipment performed or provided by or on behalf of Contractor. By endorsement to Contractor's automobile and general liability policies, the State of Nevada shall be named as an additional insured with respect to liability arising out of the activities performed by, or on behalf of Contractor. Contractor shall not commence work before Contractor has provided evidence of the required insurance in the form of a certificate of insurance and endorsement to the Contracting Agency of the State.
 - A. Workers' Compensation and Employer's Liability Insurance.
 - 1) Contractor shall provide proof of worker's compensation insurance as required per Nevada Revised Statutes Chapters 616A through 616D inclusive.
 - 2) If Contractor qualifies as a sole proprietor as defined in NRS Chapter 616A.310 and has elected to not purchase industrial insurance for himself/herself, the sole proprietor must submit to the contracting State agency a fully executed "Affidavit of Rejection of Coverage" form under NRS 616B.627 and NRS 617.210.
 - B. <u>Commercial General Liability Occurrence Form</u>. The Policy shall include bodily injury, property damage and broad form contractual liability coverage.

1)	General Aggregate	\$2,000,000
2)	Products – Completed Operations Aggregate	\$1,000,000
3)	Personal and Advertising Injury	\$1,000,000
4)	Each Occurrence	\$1,000,000

- C. <u>Automobile Liability</u>. [Delete if Contract does not involve use of motor vehicle.] The policy shall cover Bodily Injury and Property Damage for any owned, hired, and non-owned vehicles used in the performance of this Contract.
 - 1) Combined Single Limit (CSL) \$1,000,000
- D. <u>Professional Liability/Errors and Omissions Liability</u> [Delete if Contract does not involve professional services.] The policy shall cover professional misconduct or lack of ordinary skill for those positions defined in the Scope of Work of this contract. In the event that the professional liability insurance required by this Contract is written on a claims-made basis, Contractor warrants that any retroactive date under the policy shall precede the effective date of this Contract; and that either continuous coverage will be maintained or an extended discovery period will be exercised for a period of two (2) years beginning at the time work under this Contract is completed.

1) Each Claim \$1,000,000 2) Annual Aggregate \$2,000,000

Mail all required insurance documents to the Contracting Agency identified on page one of the Contract.

- 13. **WAIVER OF BREACH**. Failure to declare a breach or the actual waiver of any particular breach of the Contract or its material or nonmaterial terms by either party shall not operate as a waiver by such party of any of its rights or remedies as to any other breach.
- 14. **SEVERABILITY.** If any provision contained in this Contract is held to be unenforceable by a court of law or equity, this Contract shall be construed as if such provision did not exist and the non-enforceability of such provision shall not be held to render any other provision or provisions of this Contract unenforceable.

CETS#:	
Solicitation #:	

- 15. **STATE OWNERSHIP OF PROPRIETARY INFORMATION**. Any data or information provided by the State to Contractor and any documents or materials provided by the State to Contractor in the course of this Contract ("State Materials") shall be and remain the exclusive property of the State and all such State Materials shall be delivered into State possession by Contractor upon completion, termination, or cancellation of this Contract.
- 16. **PUBLIC RECORDS.** Pursuant to NRS 239.010, information or documents received from Contractor may be open to public inspection and copying. The State may have the duty to disclose unless a particular record is made confidential by law or a common law balance of interests.
- 17. **GENERAL WARRANTY**. Contractor warrants that all services, deliverables, and/or work products under this Contract shall be completed in a workmanlike manner consistent with standards in the trade, profession, or industry; shall conform to or exceed the specifications set forth in the incorporated attachments; and shall be fit for ordinary use, of good quality, with no material defects.
- 18. **DISCLOSURES REGARDING CURRENT OR FORMER STATE EMPLOYEES.** For the purpose of State compliance with NRS 333.705, Contractor represents and warrants that if Contractor, or any employee of Contractor who will be performing services under this Contract, is a current employee of the State or was employed by the State within the preceding 24 months, Contractor has disclosed the identity of such persons, and the services that each such person will perform, to the Contracting Agency.
- 19. **GOVERNING LAW: JURISDICTION**. This Contract and the rights and obligations of the parties hereto shall be governed by, and construed according to, the laws of the State of Nevada, without giving effect to any principle of conflict-of-law that would require the application of the law of any other jurisdiction. The parties consent to the exclusive jurisdiction of and venue in the First Judicial District Court, Carson City, Nevada for enforcement of this Contract, and consent to personal jurisdiction in such court for any action or proceeding arising out of this Contract.

CETS #:	
Solicitation #:	

20. **ENTIRE CONTRACT AND MODIFICATION**. This Contract and its Scope of Work constitute the entire agreement of the parties and as such are intended to be the complete and exclusive statement of the promises, representations, negotiations, discussions, and other agreements that may have been made in connection with the subject matter hereof. Unless otherwise expressly authorized by the terms of this Contract, no modification or amendment to this Contract shall be binding upon the parties unless the same is in writing and signed by the respective parties hereto and approved by the Office of the Attorney General and the State Board of Examiners, as required. This form of Contract, including any amendments to the Contract, is not authorized for use if the "not to exceed" value **Section 4**, **Consideration** equals or exceeds \$50,000. This Contract, and any amendments, may be executed in counterparts.

IN WITNESS WHEREOF, the parties hereto have caused this Contract to be signed and intend to be legally bound thereby.

Independent Contractor's Signature	Date	Independent Contractor's Title
State of Nevada Authorized Signature	Date	Title
State of Nevada Authorized Signature	Date	Title
State of Nevada Authorized Signature	Date	Title
		APPROVED BY BOARD OF EXAMINERS
		IN THE VED BY BOING OF EMMINERO
Signature – Clerk of the Board of Examiners		
	On:	
		Date
Approved as to form by:		
,		
	On:	
Deputy Attorney General for Attorney General		Date

AGENDA ACTION SHEET

B. C. D. E.	C. Accounts Payable Summary – No action.		
RECOMME	ENDED M	IOTION: No recommendation.	
PREPARED	BY:	Julie Strandberg, Executive Director	
MEETING 1	DATE:	January 14, 2021	
TIME REQU	UIRED:	5 minutes	
BACKGRO	UND INF	FORMATION:	

REVIEWED BY: __X___ President __X___ Secretary ___ X__ Executive Director

ACTION: ____Approved ____Approved w/Modifications ____Denied ____ Continued

TITLE: Agenda Item 20 Financial Status Reports:

CHIROPRACTIC PHYSICIANS' BOARD BANK BALANCE REPORT As of September 30, 2020

AGENDA ITEM 20A

 CHECKING ACCOUNT
 79,445.62

 SAVINGS ACCOUNT
 412,789.19

 SAVINGS ACCOUNT - Restricted
 0.00

 Paypal
 85.24

 Total Cash Balance @ 05/31/2020
 \$492,320.05

ACCOUNTS RECEIVABLE SUMMARY AS OF September 30, 2020

AGENDA ITEM 20C

A/R

 Fines
 21,521.00

 Cost Reimbursements
 40,556.38

 Total A/R
 \$62,077.38

ACCOUNTS PAYABLE SUMMARY As of September 30, 2020

AGENDA ITEM 20C

State Treasurer - Fines collected/payable 5,529.00

Total Accounts Payable \$ 5,529.00

Extraordinary Items

AGENDA ITEM 20D

*Employee Accrued Compensation as of 08/31/2020

	Vacation Hours	Sick-Leave Hours	Comp-Time Hours
Julie Standberg	45.11	1,114.28	1
Brett Canady	101.00	53.00	1

Chiropractic Physicians' Board of Nevada Income/Expense Report To Budget - CASH BASIS For the Period Ending September 30, 2020

AGENDA ITEM 20E

For the Feriod Ending September 30, 2020			
Revenue	Actual July 1, 2020 thru September 30, 2020	Budget FY 06/30/21	Variance
	2 005 00	250 050 00	050 005 00
License & Fees	2,865.00	256,850.00	253,985.00
Application & Fees	10,175.00	40,060.00	29,885.00
Interest/Gain Loss on Invest	42.40	40.500.00	(42.40)
Exam Fees	3,225.00	10,500.00	7,275.00
Reinstatement Fees	140.00	7,500.00	7,360.00
Miscellaneous	2,842.25	8,574.00	5,731.75
Reimbursement Income	950.00	4,100.00	3,150.00
TOTAL REVENUE	\$ 20,239.65	\$ 327,584.00	307,344.35
Expenses			
Background Checks	1,610.00	7,594.00	5.984.00
Banking Expenses	1,063.90	4,720.00	3,656.10
Dues & Registration	844.41	8,873.00	8,028.59
Equipment Repair	-	-	-
COMPUTER: Equipment/Software/Websites	4,207.37	16,256.00	12,048.63
Insurance	769.32	876.00	106.68
Legal & Professional	17.725.70	64,349.30	
Operating Supplies	97.50	1,900.00	1,802.50
Printing & Copying	677.56	2,322.44	
Postage	1,177.99	3,000.00 4,634.00	3,456.01
Casual Labor - Clerical	,	4,000.00	4,000.00
Personnel	-		•
Office Salaries	30,315.45	119,937.00	89,621.55
Board Salaries	450.00	6,300.00	5,850.00
Workman's Compensation	1,213.00	2,345.00	1,132.00
Retirement - PERS	8,964.61	29,208.00	20,243.39
Employee Insurance - PEBP	5,367.97	21,982.00	16,614.03
Unemployment	84.59	1,000.00	915.41
Medicare & Social Security	439.58	1,740.00	1,300.42
Payroll Processing	462.00	548.00	86.00
Rent	4,135.12	16,631.00	12,495.88
Telephone	545.70	2,320.00	1,774.30
Travel	-		-
In State	-	6,000.00	6,000.00
Out State		8,000.00	8,000.00
TOTAL EXPENSES	\$ 80,151.77	\$ 349,939.00	\$ 269,787.23
NET RESULT	\$ (59,912.12)	\$ (22,355.00)	
BEGINNING CASH BALANCE 07/01/19	547,312.94		
NET OPERATING RESULT	487,400.82		:
Equipment Purchases		2,000.00	

Chiropractic Physicians' Board of Nevada Income/Expense Report To Budget - CASH BASIS For the Period Ending September 30, 2020

AGENDA ITEM 20F

Revenue License & Fees		uly 1, 2020 thru nber 30, 2020 2.865.00	2	tual July 1, 2019 thru otember 30, 2019	V	/ariance
Application & Fees		10,175.00		13,575.00		3,400.00
Interest/Gain Loss on Invest		42.40		160.50		118.10
Exam Fees		3.225.00		6,950.00		3,725.00
Reinstatement Fees	140.00			500.00		360.00
Miscellaneous						777.99
Reimbursement Income	2,842.25			3,620.24 450.00		
	•	950.00	•			(500.00)
TOTAL REVENUE	\$	20,239.65	\$	29,740.74		9,501.09
Expenses						
Background Checks		1,610.00		2,368.75		758.75
Banking Expenses		1.063.90		1,371.28		307.38
Dues & Registration		844.41		1,895.65	1,051.24	
Equipment Repair		-		-		-
COMPUTER: Equipment/Software/Websites		4,207.37		4,109.35		(98.02)
Insurance		769.32		781.24		11.92
Legal & Professional	17,725.70			18,399.36		673.66
Operating Supplies	97.50			837.56		740.06
Printing & Copying		677.56		788.94		111.38
Postage		1,177.99		1,244.21		66.22
Casual Labor - Clerical		-		-		-
Personnel		_				
Office Salaries		30,315.45		28.903.36		(1,412.09)
Board Salaries		450.00		750.00		300.00
Workman's Compensation		1,213.00		1,458.33		245.33
Retirement - PERS		8,964.61		5,525.90		(3,438.71)
Employee Insurance - PEBP		5.367.97		5,344.93		(23.04)
Unemployment		84.59		119.80		`35.21 [′]
Medicare & Social Security		439.58		419.10		(20.48)
Payroll Processing		462.00		429.73		(32.27)
Rent		4,135.12		3,746.98		(388.14)
Telephone		545.70		745.58		`199.88 [´]
Travel		-				-
In State		-		2,531.23		2,531.23
Out State				180.64		180.64
TOTAL EXPENSES	\$	80,151.77	\$	81,951.92	\$	1,800.15
NET RESULT	\$	(59,912.12)	\$	(52,211.18)		
BEGINNING CASH BALANCE 07/01/20		543,483.13		_		
NET OPERATING RESULT	=	483,571.01	-			

CHIROPRACTIC PHYSICIANS' BOARD OF NEVADA AGENDA ACTION SHEET

TITLE: Agenda Item 21 NCA Report
RECOMMENDED MOTION:
PRESENTED BY:
MEETING DATE: January 14, 2021
TIME REQUIRED: 10 minutes
BACKGROUND INFORMATION:
REVIEWED BY: X President X Secretary X Executive Director
ACTION:ApprovedApproved w/ModificationsDenied Continued

AGENDA ACTION SHEET

TITLE: Agenda Iter	m 22 NCC	Report – No act	ion			
RECOMMENDED N	MOTION:					
PRESENTED BY:						
MEETING DATE:	January	14, 2021				
TIME REQUIRED:	15 minut	es				
BACKGROUND IN	FORMATI	ON:				
REVIEWED BY:	_ <u>X</u> F	resident X	_ Secretary	<u>X</u>	Executive Dia	rector
ACTION: App	roved	Approved w/N	Modifications		Denied	Continued

AGENDA ACTION SHEET

TITLE: Agenda Item 23 Public Interest Comments – No action This portion of the meeting is open to the public to speak on any topic NOT or today's agenda and may be limited to 3 minutes						
RECOMMENDED N	MOTION: Non-Action item.					
PREPARED BY:	Margaret Colucci, DC					
MEETING DATE:	January 14, 2021					
TIME REQUIRED:	3 minutes per person per topic					
BACKGROUND INI the agenda but no ac	FORMATION: The public may speak to the Board about any topic not or ction may be taken.					
REVIEWED BY:	X PresidentX SecretaryX Executive Director					
ACTION: App	roved Approved w/Modifications Denied Continued					

AGENDA ACTION SHEET

TITLE: Agenda Item 24 Adjournment – For possible action			
RECOMMENDED N	MOTION: Adjourn the meeting.		
PRESENTED BY:	Margaret Colucci, DC		
MEETING DATE:	January 14, 2021		
TIME REQUIRED:	2 minutes		
BACKGROUND INFORMATION: The meeting should be formally adjourned when all matters on the agenda have been addressed.			
	X President X Secretary X Executive Director		
ACTION:App	rovedApproved w/ModificationsDenied Continued		